Review



stf 62247  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 94

    Structured Review

    MedChemExpress stf 62247
    Stf 62247, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/stf/STF-62247/pmc13006433-367-69-75
    Average 94 stars, based on 2 article reviews
    stf 62247 - by Bioz Stars, 2026-11
    94/100 stars

    Images

    Related Articles

    Drug discovery:

    Article Title: HIF-activated priming of TRAIL-induced cell death determines epigenetic vulnerability in kidney cancer
    Article Snippet: The percentage of PI-positive cells was quantified.The percentage of PI-positive cells was quantified.. To validate cell death inhibitors, RCC10 (1 × 10 5 cells/well) cells were seeded onto the 12-well plate for 12 h and pre-treated for 30 min with vehicle, Necrostatin-1 (10 μM), Ferrostatin-1 (2 μM), 3-MA (1.25 mM), or AC-FLTD-CMK (10 μM), followed by 3 days of co-treatment with vehicle or respective cell death activator, including Compound6i (0.5 μM, necroptosis activator, HY-144828, MCE), RSL3 (50 nM, ferroptosis activator, HY-100218A, MCE), STF-62247 (5 μM, autophagy inducer, HY-100746, MCE), or Nigericin (1 μM, pyroptosis inducer, HY-127019, MCE).. MDA-MB-231 (1 × 10 5 cells/well) cells were pre-treated for 30 min with vehicle or Olaparib (10 μM), followed by 15 min of co-treatment with vehicle or N-Methyl-N-nitroso-N′-nitroguanidine (MNNG, 50 μM, parthanatos inducer, N -12560, Chem Service).MDA-MB-231 (1 × 10 5 cells/well) cells were pre-treated for 30 min with vehicle or Olaparib (10 μM), followed by 15 min of co-treatment with vehicle or..

    Article Title: HIF-activated priming of TRAIL-induced cell death determines epigenetic vulnerability in kidney cancer.
    Article Snippet: ssue Kit Qiagen Cat# 69504 RNeasy mini kit Qiagen Cat# 74104 KAPA mRNA HyperPrep Kit Roche Cat# 08098123702 Bioactive Compound Library Selleckchem Cat# L1700 Chemicals and recombinant proteins SGI1027 MCE HY-13962 Necrostatin-1 MCE HY-15760 Ferrostatin-1 MCE HY-100579 Olaparib MCE HY-10162 Compound6i MCE HY-100218A STF-62247 MCE HY-100746 Nigericin MCE HY-127019 Decitabine MCE HY-A0004 N-Methyl-N-n

    Article Title: HIF-activated priming of TRAIL-induced cell death determines epigenetic vulnerability in kidney cancer.
    Article Snippet: The percentage of PI-positive cells was quantified.The percentage of PI-positive cells was quantified.. To validate cell death inhibitors, RCC10 (1 × 10 5 cells/well) cells were seeded onto the 12-well plate for 12 h and pre-treated for 30 min with vehicle, Necrostatin-1 (10 μM), Ferrostatin-1 (2 μM), 3-MA (1.25 mM), or AC-FLTD-CMK (10 μM), followed by 3 days of cotreatment with vehicle or respective cell death activator, including Compound6i (0.5 μM, necroptosis activator, HY-144828, MCE), RSL3 (50 nM, ferroptosis activator, HY-100218A, MCE), STF-62247 (5 μM, autophagy inducer, HY-100746, MCE), or Nigericin (1 μM, pyroptosis inducer, HY-127019, MCE).. MDA-MB-231 (1 × 10 5 cells/well) cells were pre-treated for 30 min with vehicle or Olaparib (10 μM), followed by 15 min of co-treatment with vehicle or N-Methyl-N-nitroso-N ′ -nitroguanidine (MNNG, 50 μM, parthanatos Cell Reports Medicine 7, 102630, March 17, 2026 e3 OPEN ACCESS inducer, N-12560, Chem Service).MDA-MB-231 (1 × 10 5 cells/well) cells were pre-treated for 30 min with vehicle or Olaparib (10 μM), followed by 15 min of co-treatment with vehicle or..

    Article Title: Autophagy-amplifying nanoparticles evoke immunogenic cell death combined with anti-PD-1/PD-L1 for residual tumors immunotherapy after RFA.
    Article Snippet: Zn (NO3)2•6H2O and 2-MeIM were purchased from Aladdin Holdings Group Co., Ltd (Shanghai); PEGFA 2000, ICG, and FITC from Rixi Biotechnology Co., Ltd. (Xi’an); BMS202 (HY-19745), STF62247 (HY100746), 3-MA (HY-19312), and Chloroquine (HY17589A) from MedChemExpress (Shanghai); ethanol from Guangzhou Chemical Reagent Factory.. LC3B antibody (L7543) was purchased from Sigma; ATG5 antibody (T55766) from Abmart; p-mTOR antibody (Ser172) (#2971S) from CST; HMGB1 antibody (10,829-1-AP) from Proteintech; HRP-Goat anti-rabbit IgG(H + L) (E030120-01) from Earthox; CD4 antibody (bs-0647R), CD8 antibody (bs-4791R) from Bioss;p62 antibody (ab109012), mTOR antibody (ab137133), Calreticulin antibody (ab92516), Ki67 antibody (ab16667), Goat anti-rabbit IgG H&L (Alexa Fluor® 488) (ab150077), Goat anti-rabbit IgG H&L (Alexa Fluor® 555) (ab150078), and DAPI Staining Solution (ab228549) from Abcam.LC3B antibody (L7543) was purchased from Sigma; ATG5 antibody (T55766) from Abmart; p-mTOR antibody (Ser172) (#2971S) from CST; HMGB1 antibody (10,829-1-AP) from Proteintech; HRP-Goat anti-rabbit IgG(H + L) (E030120-01) from Earthox; CD4 antibody (bs-0647R), CD8 antibody (bs-4791R) from Bioss;p62 antibody (ab109012), mTOR antibody (ab137133),..

    Article Title: Autophagy-amplifying nanoparticles evoke immunogenic cell death combined with anti-PD-1/PD-L1 for residual tumors immunotherapy after RFA
    Article Snippet: Zn (NO3)2•6H2O and 2-MeIM were purchased from Aladdin Holdings Group Co., Ltd (Shanghai); PEG-FA 2000, ICG, and FITC from Rixi Biotechnology Co., Ltd. (Xi’an); BMS202 (HY-19745), STF62247 (HY-100746), 3-MA (HY-19312), and Chloroquine (HY-17589A) from MedChemExpress (Shanghai); ethanol from Guangzhou Chemical Reagent Factory. .. L

    Recombinant:

    Article Title: HIF-activated priming of TRAIL-induced cell death determines epigenetic vulnerability in kidney cancer
    Article Snippet: The percentage of PI-positive cells was quantified.The percentage of PI-positive cells was quantified.. To validate cell death inhibitors, RCC10 (1 × 10 5 cells/well) cells were seeded onto the 12-well plate for 12 h and pre-treated for 30 min with vehicle, Necrostatin-1 (10 μM), Ferrostatin-1 (2 μM), 3-MA (1.25 mM), or AC-FLTD-CMK (10 μM), followed by 3 days of co-treatment with vehicle or respective cell death activator, including Compound6i (0.5 μM, necroptosis activator, HY-144828, MCE), RSL3 (50 nM, ferroptosis activator, HY-100218A, MCE), STF-62247 (5 μM, autophagy inducer, HY-100746, MCE), or Nigericin (1 μM, pyroptosis inducer, HY-127019, MCE).. MDA-MB-231 (1 × 10 5 cells/well) cells were pre-treated for 30 min with vehicle or Olaparib (10 μM), followed by 15 min of co-treatment with vehicle or N-Methyl-N-nitroso-N′-nitroguanidine (MNNG, 50 μM, parthanatos inducer, N -12560, Chem Service).MDA-MB-231 (1 × 10 5 cells/well) cells were pre-treated for 30 min with vehicle or Olaparib (10 μM), followed by 15 min of co-treatment with vehicle or..

    Article Title: HIF-activated priming of TRAIL-induced cell death determines epigenetic vulnerability in kidney cancer.
    Article Snippet: ssue Kit Qiagen Cat# 69504 RNeasy mini kit Qiagen Cat# 74104 KAPA mRNA HyperPrep Kit Roche Cat# 08098123702 Bioactive Compound Library Selleckchem Cat# L1700 Chemicals and recombinant proteins SGI1027 MCE HY-13962 Necrostatin-1 MCE HY-15760 Ferrostatin-1 MCE HY-100579 Olaparib MCE HY-10162 Compound6i MCE HY-100218A STF-62247 MCE HY-100746 Nigericin MCE HY-127019 Decitabine MCE HY-A0004 N-Methyl-N-n

    Article Title: HIF-activated priming of TRAIL-induced cell death determines epigenetic vulnerability in kidney cancer.
    Article Snippet: The percentage of PI-positive cells was quantified.The percentage of PI-positive cells was quantified.. To validate cell death inhibitors, RCC10 (1 × 10 5 cells/well) cells were seeded onto the 12-well plate for 12 h and pre-treated for 30 min with vehicle, Necrostatin-1 (10 μM), Ferrostatin-1 (2 μM), 3-MA (1.25 mM), or AC-FLTD-CMK (10 μM), followed by 3 days of cotreatment with vehicle or respective cell death activator, including Compound6i (0.5 μM, necroptosis activator, HY-144828, MCE), RSL3 (50 nM, ferroptosis activator, HY-100218A, MCE), STF-62247 (5 μM, autophagy inducer, HY-100746, MCE), or Nigericin (1 μM, pyroptosis inducer, HY-127019, MCE).. MDA-MB-231 (1 × 10 5 cells/well) cells were pre-treated for 30 min with vehicle or Olaparib (10 μM), followed by 15 min of co-treatment with vehicle or N-Methyl-N-nitroso-N ′ -nitroguanidine (MNNG, 50 μM, parthanatos Cell Reports Medicine 7, 102630, March 17, 2026 e3 OPEN ACCESS inducer, N-12560, Chem Service).MDA-MB-231 (1 × 10 5 cells/well) cells were pre-treated for 30 min with vehicle or Olaparib (10 μM), followed by 15 min of co-treatment with vehicle or..

    Article Title: Autophagy-amplifying nanoparticles evoke immunogenic cell death combined with anti-PD-1/PD-L1 for residual tumors immunotherapy after RFA.
    Article Snippet: Zn (NO3)2•6H2O and 2-MeIM were purchased from Aladdin Holdings Group Co., Ltd (Shanghai); PEGFA 2000, ICG, and FITC from Rixi Biotechnology Co., Ltd. (Xi’an); BMS202 (HY-19745), STF62247 (HY100746), 3-MA (HY-19312), and Chloroquine (HY17589A) from MedChemExpress (Shanghai); ethanol from Guangzhou Chemical Reagent Factory.. LC3B antibody (L7543) was purchased from Sigma; ATG5 antibody (T55766) from Abmart; p-mTOR antibody (Ser172) (#2971S) from CST; HMGB1 antibody (10,829-1-AP) from Proteintech; HRP-Goat anti-rabbit IgG(H + L) (E030120-01) from Earthox; CD4 antibody (bs-0647R), CD8 antibody (bs-4791R) from Bioss;p62 antibody (ab109012), mTOR antibody (ab137133), Calreticulin antibody (ab92516), Ki67 antibody (ab16667), Goat anti-rabbit IgG H&L (Alexa Fluor® 488) (ab150077), Goat anti-rabbit IgG H&L (Alexa Fluor® 555) (ab150078), and DAPI Staining Solution (ab228549) from Abcam.LC3B antibody (L7543) was purchased from Sigma; ATG5 antibody (T55766) from Abmart; p-mTOR antibody (Ser172) (#2971S) from CST; HMGB1 antibody (10,829-1-AP) from Proteintech; HRP-Goat anti-rabbit IgG(H + L) (E030120-01) from Earthox; CD4 antibody (bs-0647R), CD8 antibody (bs-4791R) from Bioss;p62 antibody (ab109012), mTOR antibody (ab137133),..

    Article Title: Autophagy-amplifying nanoparticles evoke immunogenic cell death combined with anti-PD-1/PD-L1 for residual tumors immunotherapy after RFA
    Article Snippet: Zn (NO3)2•6H2O and 2-MeIM were purchased from Aladdin Holdings Group Co., Ltd (Shanghai); PEG-FA 2000, ICG, and FITC from Rixi Biotechnology Co., Ltd. (Xi’an); BMS202 (HY-19745), STF62247 (HY-100746), 3-MA (HY-19312), and Chloroquine (HY-17589A) from MedChemExpress (Shanghai); ethanol from Guangzhou Chemical Reagent Factory. .. L

    Spectroscopy:

    Article Title: HIF-activated priming of TRAIL-induced cell death determines epigenetic vulnerability in kidney cancer
    Article Snippet: The percentage of PI-positive cells was quantified.The percentage of PI-positive cells was quantified.. To validate cell death inhibitors, RCC10 (1 × 10 5 cells/well) cells were seeded onto the 12-well plate for 12 h and pre-treated for 30 min with vehicle, Necrostatin-1 (10 μM), Ferrostatin-1 (2 μM), 3-MA (1.25 mM), or AC-FLTD-CMK (10 μM), followed by 3 days of co-treatment with vehicle or respective cell death activator, including Compound6i (0.5 μM, necroptosis activator, HY-144828, MCE), RSL3 (50 nM, ferroptosis activator, HY-100218A, MCE), STF-62247 (5 μM, autophagy inducer, HY-100746, MCE), or Nigericin (1 μM, pyroptosis inducer, HY-127019, MCE).. MDA-MB-231 (1 × 10 5 cells/well) cells were pre-treated for 30 min with vehicle or Olaparib (10 μM), followed by 15 min of co-treatment with vehicle or N-Methyl-N-nitroso-N′-nitroguanidine (MNNG, 50 μM, parthanatos inducer, N -12560, Chem Service).MDA-MB-231 (1 × 10 5 cells/well) cells were pre-treated for 30 min with vehicle or Olaparib (10 μM), followed by 15 min of co-treatment with vehicle or..

    Article Title: HIF-activated priming of TRAIL-induced cell death determines epigenetic vulnerability in kidney cancer.
    Article Snippet: ssue Kit Qiagen Cat# 69504 RNeasy mini kit Qiagen Cat# 74104 KAPA mRNA HyperPrep Kit Roche Cat# 08098123702 Bioactive Compound Library Selleckchem Cat# L1700 Chemicals and recombinant proteins SGI1027 MCE HY-13962 Necrostatin-1 MCE HY-15760 Ferrostatin-1 MCE HY-100579 Olaparib MCE HY-10162 Compound6i MCE HY-100218A STF-62247 MCE HY-100746 Nigericin MCE HY-127019 Decitabine MCE HY-A0004 N-Methyl-N-n

    Article Title: HIF-activated priming of TRAIL-induced cell death determines epigenetic vulnerability in kidney cancer.
    Article Snippet: The percentage of PI-positive cells was quantified.The percentage of PI-positive cells was quantified.. To validate cell death inhibitors, RCC10 (1 × 10 5 cells/well) cells were seeded onto the 12-well plate for 12 h and pre-treated for 30 min with vehicle, Necrostatin-1 (10 μM), Ferrostatin-1 (2 μM), 3-MA (1.25 mM), or AC-FLTD-CMK (10 μM), followed by 3 days of cotreatment with vehicle or respective cell death activator, including Compound6i (0.5 μM, necroptosis activator, HY-144828, MCE), RSL3 (50 nM, ferroptosis activator, HY-100218A, MCE), STF-62247 (5 μM, autophagy inducer, HY-100746, MCE), or Nigericin (1 μM, pyroptosis inducer, HY-127019, MCE).. MDA-MB-231 (1 × 10 5 cells/well) cells were pre-treated for 30 min with vehicle or Olaparib (10 μM), followed by 15 min of co-treatment with vehicle or N-Methyl-N-nitroso-N ′ -nitroguanidine (MNNG, 50 μM, parthanatos Cell Reports Medicine 7, 102630, March 17, 2026 e3 OPEN ACCESS inducer, N-12560, Chem Service).MDA-MB-231 (1 × 10 5 cells/well) cells were pre-treated for 30 min with vehicle or Olaparib (10 μM), followed by 15 min of co-treatment with vehicle or..

    Article Title: Autophagy-amplifying nanoparticles evoke immunogenic cell death combined with anti-PD-1/PD-L1 for residual tumors immunotherapy after RFA.
    Article Snippet: Zn (NO3)2•6H2O and 2-MeIM were purchased from Aladdin Holdings Group Co., Ltd (Shanghai); PEGFA 2000, ICG, and FITC from Rixi Biotechnology Co., Ltd. (Xi’an); BMS202 (HY-19745), STF62247 (HY100746), 3-MA (HY-19312), and Chloroquine (HY17589A) from MedChemExpress (Shanghai); ethanol from Guangzhou Chemical Reagent Factory.. LC3B antibody (L7543) was purchased from Sigma; ATG5 antibody (T55766) from Abmart; p-mTOR antibody (Ser172) (#2971S) from CST; HMGB1 antibody (10,829-1-AP) from Proteintech; HRP-Goat anti-rabbit IgG(H + L) (E030120-01) from Earthox; CD4 antibody (bs-0647R), CD8 antibody (bs-4791R) from Bioss;p62 antibody (ab109012), mTOR antibody (ab137133), Calreticulin antibody (ab92516), Ki67 antibody (ab16667), Goat anti-rabbit IgG H&L (Alexa Fluor® 488) (ab150077), Goat anti-rabbit IgG H&L (Alexa Fluor® 555) (ab150078), and DAPI Staining Solution (ab228549) from Abcam.LC3B antibody (L7543) was purchased from Sigma; ATG5 antibody (T55766) from Abmart; p-mTOR antibody (Ser172) (#2971S) from CST; HMGB1 antibody (10,829-1-AP) from Proteintech; HRP-Goat anti-rabbit IgG(H + L) (E030120-01) from Earthox; CD4 antibody (bs-0647R), CD8 antibody (bs-4791R) from Bioss;p62 antibody (ab109012), mTOR antibody (ab137133),..

    Article Title: Autophagy-amplifying nanoparticles evoke immunogenic cell death combined with anti-PD-1/PD-L1 for residual tumors immunotherapy after RFA
    Article Snippet: Zn (NO3)2•6H2O and 2-MeIM were purchased from Aladdin Holdings Group Co., Ltd (Shanghai); PEG-FA 2000, ICG, and FITC from Rixi Biotechnology Co., Ltd. (Xi’an); BMS202 (HY-19745), STF62247 (HY-100746), 3-MA (HY-19312), and Chloroquine (HY-17589A) from MedChemExpress (Shanghai); ethanol from Guangzhou Chemical Reagent Factory. .. L

    Transmission Assay:

    Article Title: HIF-activated priming of TRAIL-induced cell death determines epigenetic vulnerability in kidney cancer
    Article Snippet: The percentage of PI-positive cells was quantified.The percentage of PI-positive cells was quantified.. To validate cell death inhibitors, RCC10 (1 × 10 5 cells/well) cells were seeded onto the 12-well plate for 12 h and pre-treated for 30 min with vehicle, Necrostatin-1 (10 μM), Ferrostatin-1 (2 μM), 3-MA (1.25 mM), or AC-FLTD-CMK (10 μM), followed by 3 days of co-treatment with vehicle or respective cell death activator, including Compound6i (0.5 μM, necroptosis activator, HY-144828, MCE), RSL3 (50 nM, ferroptosis activator, HY-100218A, MCE), STF-62247 (5 μM, autophagy inducer, HY-100746, MCE), or Nigericin (1 μM, pyroptosis inducer, HY-127019, MCE).. MDA-MB-231 (1 × 10 5 cells/well) cells were pre-treated for 30 min with vehicle or Olaparib (10 μM), followed by 15 min of co-treatment with vehicle or N-Methyl-N-nitroso-N′-nitroguanidine (MNNG, 50 μM, parthanatos inducer, N -12560, Chem Service).MDA-MB-231 (1 × 10 5 cells/well) cells were pre-treated for 30 min with vehicle or Olaparib (10 μM), followed by 15 min of co-treatment with vehicle or..

    Article Title: HIF-activated priming of TRAIL-induced cell death determines epigenetic vulnerability in kidney cancer.
    Article Snippet: ssue Kit Qiagen Cat# 69504 RNeasy mini kit Qiagen Cat# 74104 KAPA mRNA HyperPrep Kit Roche Cat# 08098123702 Bioactive Compound Library Selleckchem Cat# L1700 Chemicals and recombinant proteins SGI1027 MCE HY-13962 Necrostatin-1 MCE HY-15760 Ferrostatin-1 MCE HY-100579 Olaparib MCE HY-10162 Compound6i MCE HY-100218A STF-62247 MCE HY-100746 Nigericin MCE HY-127019 Decitabine MCE HY-A0004 N-Methyl-N-n

    Article Title: HIF-activated priming of TRAIL-induced cell death determines epigenetic vulnerability in kidney cancer.
    Article Snippet: The percentage of PI-positive cells was quantified.The percentage of PI-positive cells was quantified.. To validate cell death inhibitors, RCC10 (1 × 10 5 cells/well) cells were seeded onto the 12-well plate for 12 h and pre-treated for 30 min with vehicle, Necrostatin-1 (10 μM), Ferrostatin-1 (2 μM), 3-MA (1.25 mM), or AC-FLTD-CMK (10 μM), followed by 3 days of cotreatment with vehicle or respective cell death activator, including Compound6i (0.5 μM, necroptosis activator, HY-144828, MCE), RSL3 (50 nM, ferroptosis activator, HY-100218A, MCE), STF-62247 (5 μM, autophagy inducer, HY-100746, MCE), or Nigericin (1 μM, pyroptosis inducer, HY-127019, MCE).. MDA-MB-231 (1 × 10 5 cells/well) cells were pre-treated for 30 min with vehicle or Olaparib (10 μM), followed by 15 min of co-treatment with vehicle or N-Methyl-N-nitroso-N ′ -nitroguanidine (MNNG, 50 μM, parthanatos Cell Reports Medicine 7, 102630, March 17, 2026 e3 OPEN ACCESS inducer, N-12560, Chem Service).MDA-MB-231 (1 × 10 5 cells/well) cells were pre-treated for 30 min with vehicle or Olaparib (10 μM), followed by 15 min of co-treatment with vehicle or..

    Article Title: Autophagy-amplifying nanoparticles evoke immunogenic cell death combined with anti-PD-1/PD-L1 for residual tumors immunotherapy after RFA.
    Article Snippet: Zn (NO3)2•6H2O and 2-MeIM were purchased from Aladdin Holdings Group Co., Ltd (Shanghai); PEGFA 2000, ICG, and FITC from Rixi Biotechnology Co., Ltd. (Xi’an); BMS202 (HY-19745), STF62247 (HY100746), 3-MA (HY-19312), and Chloroquine (HY17589A) from MedChemExpress (Shanghai); ethanol from Guangzhou Chemical Reagent Factory.. LC3B antibody (L7543) was purchased from Sigma; ATG5 antibody (T55766) from Abmart; p-mTOR antibody (Ser172) (#2971S) from CST; HMGB1 antibody (10,829-1-AP) from Proteintech; HRP-Goat anti-rabbit IgG(H + L) (E030120-01) from Earthox; CD4 antibody (bs-0647R), CD8 antibody (bs-4791R) from Bioss;p62 antibody (ab109012), mTOR antibody (ab137133), Calreticulin antibody (ab92516), Ki67 antibody (ab16667), Goat anti-rabbit IgG H&L (Alexa Fluor® 488) (ab150077), Goat anti-rabbit IgG H&L (Alexa Fluor® 555) (ab150078), and DAPI Staining Solution (ab228549) from Abcam.LC3B antibody (L7543) was purchased from Sigma; ATG5 antibody (T55766) from Abmart; p-mTOR antibody (Ser172) (#2971S) from CST; HMGB1 antibody (10,829-1-AP) from Proteintech; HRP-Goat anti-rabbit IgG(H + L) (E030120-01) from Earthox; CD4 antibody (bs-0647R), CD8 antibody (bs-4791R) from Bioss;p62 antibody (ab109012), mTOR antibody (ab137133),..

    Article Title: Autophagy-amplifying nanoparticles evoke immunogenic cell death combined with anti-PD-1/PD-L1 for residual tumors immunotherapy after RFA
    Article Snippet: Zn (NO3)2•6H2O and 2-MeIM were purchased from Aladdin Holdings Group Co., Ltd (Shanghai); PEG-FA 2000, ICG, and FITC from Rixi Biotechnology Co., Ltd. (Xi’an); BMS202 (HY-19745), STF62247 (HY-100746), 3-MA (HY-19312), and Chloroquine (HY-17589A) from MedChemExpress (Shanghai); ethanol from Guangzhou Chemical Reagent Factory. .. L

    Western Blot:

    Article Title: HIF-activated priming of TRAIL-induced cell death determines epigenetic vulnerability in kidney cancer
    Article Snippet: The percentage of PI-positive cells was quantified.The percentage of PI-positive cells was quantified.. To validate cell death inhibitors, RCC10 (1 × 10 5 cells/well) cells were seeded onto the 12-well plate for 12 h and pre-treated for 30 min with vehicle, Necrostatin-1 (10 μM), Ferrostatin-1 (2 μM), 3-MA (1.25 mM), or AC-FLTD-CMK (10 μM), followed by 3 days of co-treatment with vehicle or respective cell death activator, including Compound6i (0.5 μM, necroptosis activator, HY-144828, MCE), RSL3 (50 nM, ferroptosis activator, HY-100218A, MCE), STF-62247 (5 μM, autophagy inducer, HY-100746, MCE), or Nigericin (1 μM, pyroptosis inducer, HY-127019, MCE).. MDA-MB-231 (1 × 10 5 cells/well) cells were pre-treated for 30 min with vehicle or Olaparib (10 μM), followed by 15 min of co-treatment with vehicle or N-Methyl-N-nitroso-N′-nitroguanidine (MNNG, 50 μM, parthanatos inducer, N -12560, Chem Service).MDA-MB-231 (1 × 10 5 cells/well) cells were pre-treated for 30 min with vehicle or Olaparib (10 μM), followed by 15 min of co-treatment with vehicle or..

    Article Title: HIF-activated priming of TRAIL-induced cell death determines epigenetic vulnerability in kidney cancer.
    Article Snippet: ssue Kit Qiagen Cat# 69504 RNeasy mini kit Qiagen Cat# 74104 KAPA mRNA HyperPrep Kit Roche Cat# 08098123702 Bioactive Compound Library Selleckchem Cat# L1700 Chemicals and recombinant proteins SGI1027 MCE HY-13962 Necrostatin-1 MCE HY-15760 Ferrostatin-1 MCE HY-100579 Olaparib MCE HY-10162 Compound6i MCE HY-100218A STF-62247 MCE HY-100746 Nigericin MCE HY-127019 Decitabine MCE HY-A0004 N-Methyl-N-n

    Article Title: HIF-activated priming of TRAIL-induced cell death determines epigenetic vulnerability in kidney cancer.
    Article Snippet: The percentage of PI-positive cells was quantified.The percentage of PI-positive cells was quantified.. To validate cell death inhibitors, RCC10 (1 × 10 5 cells/well) cells were seeded onto the 12-well plate for 12 h and pre-treated for 30 min with vehicle, Necrostatin-1 (10 μM), Ferrostatin-1 (2 μM), 3-MA (1.25 mM), or AC-FLTD-CMK (10 μM), followed by 3 days of cotreatment with vehicle or respective cell death activator, including Compound6i (0.5 μM, necroptosis activator, HY-144828, MCE), RSL3 (50 nM, ferroptosis activator, HY-100218A, MCE), STF-62247 (5 μM, autophagy inducer, HY-100746, MCE), or Nigericin (1 μM, pyroptosis inducer, HY-127019, MCE).. MDA-MB-231 (1 × 10 5 cells/well) cells were pre-treated for 30 min with vehicle or Olaparib (10 μM), followed by 15 min of co-treatment with vehicle or N-Methyl-N-nitroso-N ′ -nitroguanidine (MNNG, 50 μM, parthanatos Cell Reports Medicine 7, 102630, March 17, 2026 e3 OPEN ACCESS inducer, N-12560, Chem Service).MDA-MB-231 (1 × 10 5 cells/well) cells were pre-treated for 30 min with vehicle or Olaparib (10 μM), followed by 15 min of co-treatment with vehicle or..

    Article Title: Autophagy-amplifying nanoparticles evoke immunogenic cell death combined with anti-PD-1/PD-L1 for residual tumors immunotherapy after RFA.
    Article Snippet: Zn (NO3)2•6H2O and 2-MeIM were purchased from Aladdin Holdings Group Co., Ltd (Shanghai); PEGFA 2000, ICG, and FITC from Rixi Biotechnology Co., Ltd. (Xi’an); BMS202 (HY-19745), STF62247 (HY100746), 3-MA (HY-19312), and Chloroquine (HY17589A) from MedChemExpress (Shanghai); ethanol from Guangzhou Chemical Reagent Factory.. LC3B antibody (L7543) was purchased from Sigma; ATG5 antibody (T55766) from Abmart; p-mTOR antibody (Ser172) (#2971S) from CST; HMGB1 antibody (10,829-1-AP) from Proteintech; HRP-Goat anti-rabbit IgG(H + L) (E030120-01) from Earthox; CD4 antibody (bs-0647R), CD8 antibody (bs-4791R) from Bioss;p62 antibody (ab109012), mTOR antibody (ab137133), Calreticulin antibody (ab92516), Ki67 antibody (ab16667), Goat anti-rabbit IgG H&L (Alexa Fluor® 488) (ab150077), Goat anti-rabbit IgG H&L (Alexa Fluor® 555) (ab150078), and DAPI Staining Solution (ab228549) from Abcam.LC3B antibody (L7543) was purchased from Sigma; ATG5 antibody (T55766) from Abmart; p-mTOR antibody (Ser172) (#2971S) from CST; HMGB1 antibody (10,829-1-AP) from Proteintech; HRP-Goat anti-rabbit IgG(H + L) (E030120-01) from Earthox; CD4 antibody (bs-0647R), CD8 antibody (bs-4791R) from Bioss;p62 antibody (ab109012), mTOR antibody (ab137133),..

    Article Title: Autophagy-amplifying nanoparticles evoke immunogenic cell death combined with anti-PD-1/PD-L1 for residual tumors immunotherapy after RFA
    Article Snippet: Zn (NO3)2•6H2O and 2-MeIM were purchased from Aladdin Holdings Group Co., Ltd (Shanghai); PEG-FA 2000, ICG, and FITC from Rixi Biotechnology Co., Ltd. (Xi’an); BMS202 (HY-19745), STF62247 (HY-100746), 3-MA (HY-19312), and Chloroquine (HY-17589A) from MedChemExpress (Shanghai); ethanol from Guangzhou Chemical Reagent Factory. .. L

    Transfection:

    Article Title: HIF-activated priming of TRAIL-induced cell death determines epigenetic vulnerability in kidney cancer
    Article Snippet: The percentage of PI-positive cells was quantified.The percentage of PI-positive cells was quantified.. To validate cell death inhibitors, RCC10 (1 × 10 5 cells/well) cells were seeded onto the 12-well plate for 12 h and pre-treated for 30 min with vehicle, Necrostatin-1 (10 μM), Ferrostatin-1 (2 μM), 3-MA (1.25 mM), or AC-FLTD-CMK (10 μM), followed by 3 days of co-treatment with vehicle or respective cell death activator, including Compound6i (0.5 μM, necroptosis activator, HY-144828, MCE), RSL3 (50 nM, ferroptosis activator, HY-100218A, MCE), STF-62247 (5 μM, autophagy inducer, HY-100746, MCE), or Nigericin (1 μM, pyroptosis inducer, HY-127019, MCE).. MDA-MB-231 (1 × 10 5 cells/well) cells were pre-treated for 30 min with vehicle or Olaparib (10 μM), followed by 15 min of co-treatment with vehicle or N-Methyl-N-nitroso-N′-nitroguanidine (MNNG, 50 μM, parthanatos inducer, N -12560, Chem Service).MDA-MB-231 (1 × 10 5 cells/well) cells were pre-treated for 30 min with vehicle or Olaparib (10 μM), followed by 15 min of co-treatment with vehicle or..

    Article Title: HIF-activated priming of TRAIL-induced cell death determines epigenetic vulnerability in kidney cancer.
    Article Snippet: ssue Kit Qiagen Cat# 69504 RNeasy mini kit Qiagen Cat# 74104 KAPA mRNA HyperPrep Kit Roche Cat# 08098123702 Bioactive Compound Library Selleckchem Cat# L1700 Chemicals and recombinant proteins SGI1027 MCE HY-13962 Necrostatin-1 MCE HY-15760 Ferrostatin-1 MCE HY-100579 Olaparib MCE HY-10162 Compound6i MCE HY-100218A STF-62247 MCE HY-100746 Nigericin MCE HY-127019 Decitabine MCE HY-A0004 N-Methyl-N-n

    Article Title: HIF-activated priming of TRAIL-induced cell death determines epigenetic vulnerability in kidney cancer.
    Article Snippet: The percentage of PI-positive cells was quantified.The percentage of PI-positive cells was quantified.. To validate cell death inhibitors, RCC10 (1 × 10 5 cells/well) cells were seeded onto the 12-well plate for 12 h and pre-treated for 30 min with vehicle, Necrostatin-1 (10 μM), Ferrostatin-1 (2 μM), 3-MA (1.25 mM), or AC-FLTD-CMK (10 μM), followed by 3 days of cotreatment with vehicle or respective cell death activator, including Compound6i (0.5 μM, necroptosis activator, HY-144828, MCE), RSL3 (50 nM, ferroptosis activator, HY-100218A, MCE), STF-62247 (5 μM, autophagy inducer, HY-100746, MCE), or Nigericin (1 μM, pyroptosis inducer, HY-127019, MCE).. MDA-MB-231 (1 × 10 5 cells/well) cells were pre-treated for 30 min with vehicle or Olaparib (10 μM), followed by 15 min of co-treatment with vehicle or N-Methyl-N-nitroso-N ′ -nitroguanidine (MNNG, 50 μM, parthanatos Cell Reports Medicine 7, 102630, March 17, 2026 e3 OPEN ACCESS inducer, N-12560, Chem Service).MDA-MB-231 (1 × 10 5 cells/well) cells were pre-treated for 30 min with vehicle or Olaparib (10 μM), followed by 15 min of co-treatment with vehicle or..

    Article Title: Autophagy-amplifying nanoparticles evoke immunogenic cell death combined with anti-PD-1/PD-L1 for residual tumors immunotherapy after RFA.
    Article Snippet: Zn (NO3)2•6H2O and 2-MeIM were purchased from Aladdin Holdings Group Co., Ltd (Shanghai); PEGFA 2000, ICG, and FITC from Rixi Biotechnology Co., Ltd. (Xi’an); BMS202 (HY-19745), STF62247 (HY100746), 3-MA (HY-19312), and Chloroquine (HY17589A) from MedChemExpress (Shanghai); ethanol from Guangzhou Chemical Reagent Factory.. LC3B antibody (L7543) was purchased from Sigma; ATG5 antibody (T55766) from Abmart; p-mTOR antibody (Ser172) (#2971S) from CST; HMGB1 antibody (10,829-1-AP) from Proteintech; HRP-Goat anti-rabbit IgG(H + L) (E030120-01) from Earthox; CD4 antibody (bs-0647R), CD8 antibody (bs-4791R) from Bioss;p62 antibody (ab109012), mTOR antibody (ab137133), Calreticulin antibody (ab92516), Ki67 antibody (ab16667), Goat anti-rabbit IgG H&L (Alexa Fluor® 488) (ab150077), Goat anti-rabbit IgG H&L (Alexa Fluor® 555) (ab150078), and DAPI Staining Solution (ab228549) from Abcam.LC3B antibody (L7543) was purchased from Sigma; ATG5 antibody (T55766) from Abmart; p-mTOR antibody (Ser172) (#2971S) from CST; HMGB1 antibody (10,829-1-AP) from Proteintech; HRP-Goat anti-rabbit IgG(H + L) (E030120-01) from Earthox; CD4 antibody (bs-0647R), CD8 antibody (bs-4791R) from Bioss;p62 antibody (ab109012), mTOR antibody (ab137133),..

    Article Title: Autophagy-amplifying nanoparticles evoke immunogenic cell death combined with anti-PD-1/PD-L1 for residual tumors immunotherapy after RFA
    Article Snippet: Zn (NO3)2•6H2O and 2-MeIM were purchased from Aladdin Holdings Group Co., Ltd (Shanghai); PEG-FA 2000, ICG, and FITC from Rixi Biotechnology Co., Ltd. (Xi’an); BMS202 (HY-19745), STF62247 (HY-100746), 3-MA (HY-19312), and Chloroquine (HY-17589A) from MedChemExpress (Shanghai); ethanol from Guangzhou Chemical Reagent Factory. .. L

    Plasmid Preparation:

    Article Title: HIF-activated priming of TRAIL-induced cell death determines epigenetic vulnerability in kidney cancer
    Article Snippet: The percentage of PI-positive cells was quantified.The percentage of PI-positive cells was quantified.. To validate cell death inhibitors, RCC10 (1 × 10 5 cells/well) cells were seeded onto the 12-well plate for 12 h and pre-treated for 30 min with vehicle, Necrostatin-1 (10 μM), Ferrostatin-1 (2 μM), 3-MA (1.25 mM), or AC-FLTD-CMK (10 μM), followed by 3 days of co-treatment with vehicle or respective cell death activator, including Compound6i (0.5 μM, necroptosis activator, HY-144828, MCE), RSL3 (50 nM, ferroptosis activator, HY-100218A, MCE), STF-62247 (5 μM, autophagy inducer, HY-100746, MCE), or Nigericin (1 μM, pyroptosis inducer, HY-127019, MCE).. MDA-MB-231 (1 × 10 5 cells/well) cells were pre-treated for 30 min with vehicle or Olaparib (10 μM), followed by 15 min of co-treatment with vehicle or N-Methyl-N-nitroso-N′-nitroguanidine (MNNG, 50 μM, parthanatos inducer, N -12560, Chem Service).MDA-MB-231 (1 × 10 5 cells/well) cells were pre-treated for 30 min with vehicle or Olaparib (10 μM), followed by 15 min of co-treatment with vehicle or..

    Article Title: HIF-activated priming of TRAIL-induced cell death determines epigenetic vulnerability in kidney cancer.
    Article Snippet: ssue Kit Qiagen Cat# 69504 RNeasy mini kit Qiagen Cat# 74104 KAPA mRNA HyperPrep Kit Roche Cat# 08098123702 Bioactive Compound Library Selleckchem Cat# L1700 Chemicals and recombinant proteins SGI1027 MCE HY-13962 Necrostatin-1 MCE HY-15760 Ferrostatin-1 MCE HY-100579 Olaparib MCE HY-10162 Compound6i MCE HY-100218A STF-62247 MCE HY-100746 Nigericin MCE HY-127019 Decitabine MCE HY-A0004 N-Methyl-N-n

    Article Title: HIF-activated priming of TRAIL-induced cell death determines epigenetic vulnerability in kidney cancer.
    Article Snippet: The percentage of PI-positive cells was quantified.The percentage of PI-positive cells was quantified.. To validate cell death inhibitors, RCC10 (1 × 10 5 cells/well) cells were seeded onto the 12-well plate for 12 h and pre-treated for 30 min with vehicle, Necrostatin-1 (10 μM), Ferrostatin-1 (2 μM), 3-MA (1.25 mM), or AC-FLTD-CMK (10 μM), followed by 3 days of cotreatment with vehicle or respective cell death activator, including Compound6i (0.5 μM, necroptosis activator, HY-144828, MCE), RSL3 (50 nM, ferroptosis activator, HY-100218A, MCE), STF-62247 (5 μM, autophagy inducer, HY-100746, MCE), or Nigericin (1 μM, pyroptosis inducer, HY-127019, MCE).. MDA-MB-231 (1 × 10 5 cells/well) cells were pre-treated for 30 min with vehicle or Olaparib (10 μM), followed by 15 min of co-treatment with vehicle or N-Methyl-N-nitroso-N ′ -nitroguanidine (MNNG, 50 μM, parthanatos Cell Reports Medicine 7, 102630, March 17, 2026 e3 OPEN ACCESS inducer, N-12560, Chem Service).MDA-MB-231 (1 × 10 5 cells/well) cells were pre-treated for 30 min with vehicle or Olaparib (10 μM), followed by 15 min of co-treatment with vehicle or..

    Article Title: Autophagy-amplifying nanoparticles evoke immunogenic cell death combined with anti-PD-1/PD-L1 for residual tumors immunotherapy after RFA.
    Article Snippet: Zn (NO3)2•6H2O and 2-MeIM were purchased from Aladdin Holdings Group Co., Ltd (Shanghai); PEGFA 2000, ICG, and FITC from Rixi Biotechnology Co., Ltd. (Xi’an); BMS202 (HY-19745), STF62247 (HY100746), 3-MA (HY-19312), and Chloroquine (HY17589A) from MedChemExpress (Shanghai); ethanol from Guangzhou Chemical Reagent Factory.. LC3B antibody (L7543) was purchased from Sigma; ATG5 antibody (T55766) from Abmart; p-mTOR antibody (Ser172) (#2971S) from CST; HMGB1 antibody (10,829-1-AP) from Proteintech; HRP-Goat anti-rabbit IgG(H + L) (E030120-01) from Earthox; CD4 antibody (bs-0647R), CD8 antibody (bs-4791R) from Bioss;p62 antibody (ab109012), mTOR antibody (ab137133), Calreticulin antibody (ab92516), Ki67 antibody (ab16667), Goat anti-rabbit IgG H&L (Alexa Fluor® 488) (ab150077), Goat anti-rabbit IgG H&L (Alexa Fluor® 555) (ab150078), and DAPI Staining Solution (ab228549) from Abcam.LC3B antibody (L7543) was purchased from Sigma; ATG5 antibody (T55766) from Abmart; p-mTOR antibody (Ser172) (#2971S) from CST; HMGB1 antibody (10,829-1-AP) from Proteintech; HRP-Goat anti-rabbit IgG(H + L) (E030120-01) from Earthox; CD4 antibody (bs-0647R), CD8 antibody (bs-4791R) from Bioss;p62 antibody (ab109012), mTOR antibody (ab137133),..

    Article Title: Autophagy-amplifying nanoparticles evoke immunogenic cell death combined with anti-PD-1/PD-L1 for residual tumors immunotherapy after RFA
    Article Snippet: Zn (NO3)2•6H2O and 2-MeIM were purchased from Aladdin Holdings Group Co., Ltd (Shanghai); PEG-FA 2000, ICG, and FITC from Rixi Biotechnology Co., Ltd. (Xi’an); BMS202 (HY-19745), STF62247 (HY-100746), 3-MA (HY-19312), and Chloroquine (HY-17589A) from MedChemExpress (Shanghai); ethanol from Guangzhou Chemical Reagent Factory. .. L

    Microscopy:

    Article Title: HIF-activated priming of TRAIL-induced cell death determines epigenetic vulnerability in kidney cancer
    Article Snippet: The percentage of PI-positive cells was quantified.The percentage of PI-positive cells was quantified.. To validate cell death inhibitors, RCC10 (1 × 10 5 cells/well) cells were seeded onto the 12-well plate for 12 h and pre-treated for 30 min with vehicle, Necrostatin-1 (10 μM), Ferrostatin-1 (2 μM), 3-MA (1.25 mM), or AC-FLTD-CMK (10 μM), followed by 3 days of co-treatment with vehicle or respective cell death activator, including Compound6i (0.5 μM, necroptosis activator, HY-144828, MCE), RSL3 (50 nM, ferroptosis activator, HY-100218A, MCE), STF-62247 (5 μM, autophagy inducer, HY-100746, MCE), or Nigericin (1 μM, pyroptosis inducer, HY-127019, MCE).. MDA-MB-231 (1 × 10 5 cells/well) cells were pre-treated for 30 min with vehicle or Olaparib (10 μM), followed by 15 min of co-treatment with vehicle or N-Methyl-N-nitroso-N′-nitroguanidine (MNNG, 50 μM, parthanatos inducer, N -12560, Chem Service).MDA-MB-231 (1 × 10 5 cells/well) cells were pre-treated for 30 min with vehicle or Olaparib (10 μM), followed by 15 min of co-treatment with vehicle or..

    Article Title: HIF-activated priming of TRAIL-induced cell death determines epigenetic vulnerability in kidney cancer.
    Article Snippet: ssue Kit Qiagen Cat# 69504 RNeasy mini kit Qiagen Cat# 74104 KAPA mRNA HyperPrep Kit Roche Cat# 08098123702 Bioactive Compound Library Selleckchem Cat# L1700 Chemicals and recombinant proteins SGI1027 MCE HY-13962 Necrostatin-1 MCE HY-15760 Ferrostatin-1 MCE HY-100579 Olaparib MCE HY-10162 Compound6i MCE HY-100218A STF-62247 MCE HY-100746 Nigericin MCE HY-127019 Decitabine MCE HY-A0004 N-Methyl-N-n

    Article Title: HIF-activated priming of TRAIL-induced cell death determines epigenetic vulnerability in kidney cancer.
    Article Snippet: The percentage of PI-positive cells was quantified.The percentage of PI-positive cells was quantified.. To validate cell death inhibitors, RCC10 (1 × 10 5 cells/well) cells were seeded onto the 12-well plate for 12 h and pre-treated for 30 min with vehicle, Necrostatin-1 (10 μM), Ferrostatin-1 (2 μM), 3-MA (1.25 mM), or AC-FLTD-CMK (10 μM), followed by 3 days of cotreatment with vehicle or respective cell death activator, including Compound6i (0.5 μM, necroptosis activator, HY-144828, MCE), RSL3 (50 nM, ferroptosis activator, HY-100218A, MCE), STF-62247 (5 μM, autophagy inducer, HY-100746, MCE), or Nigericin (1 μM, pyroptosis inducer, HY-127019, MCE).. MDA-MB-231 (1 × 10 5 cells/well) cells were pre-treated for 30 min with vehicle or Olaparib (10 μM), followed by 15 min of co-treatment with vehicle or N-Methyl-N-nitroso-N ′ -nitroguanidine (MNNG, 50 μM, parthanatos Cell Reports Medicine 7, 102630, March 17, 2026 e3 OPEN ACCESS inducer, N-12560, Chem Service).MDA-MB-231 (1 × 10 5 cells/well) cells were pre-treated for 30 min with vehicle or Olaparib (10 μM), followed by 15 min of co-treatment with vehicle or..

    Article Title: Autophagy-amplifying nanoparticles evoke immunogenic cell death combined with anti-PD-1/PD-L1 for residual tumors immunotherapy after RFA.
    Article Snippet: Zn (NO3)2•6H2O and 2-MeIM were purchased from Aladdin Holdings Group Co., Ltd (Shanghai); PEGFA 2000, ICG, and FITC from Rixi Biotechnology Co., Ltd. (Xi’an); BMS202 (HY-19745), STF62247 (HY100746), 3-MA (HY-19312), and Chloroquine (HY17589A) from MedChemExpress (Shanghai); ethanol from Guangzhou Chemical Reagent Factory.. LC3B antibody (L7543) was purchased from Sigma; ATG5 antibody (T55766) from Abmart; p-mTOR antibody (Ser172) (#2971S) from CST; HMGB1 antibody (10,829-1-AP) from Proteintech; HRP-Goat anti-rabbit IgG(H + L) (E030120-01) from Earthox; CD4 antibody (bs-0647R), CD8 antibody (bs-4791R) from Bioss;p62 antibody (ab109012), mTOR antibody (ab137133), Calreticulin antibody (ab92516), Ki67 antibody (ab16667), Goat anti-rabbit IgG H&L (Alexa Fluor® 488) (ab150077), Goat anti-rabbit IgG H&L (Alexa Fluor® 555) (ab150078), and DAPI Staining Solution (ab228549) from Abcam.LC3B antibody (L7543) was purchased from Sigma; ATG5 antibody (T55766) from Abmart; p-mTOR antibody (Ser172) (#2971S) from CST; HMGB1 antibody (10,829-1-AP) from Proteintech; HRP-Goat anti-rabbit IgG(H + L) (E030120-01) from Earthox; CD4 antibody (bs-0647R), CD8 antibody (bs-4791R) from Bioss;p62 antibody (ab109012), mTOR antibody (ab137133),..

    Article Title: Autophagy-amplifying nanoparticles evoke immunogenic cell death combined with anti-PD-1/PD-L1 for residual tumors immunotherapy after RFA
    Article Snippet: Zn (NO3)2•6H2O and 2-MeIM were purchased from Aladdin Holdings Group Co., Ltd (Shanghai); PEG-FA 2000, ICG, and FITC from Rixi Biotechnology Co., Ltd. (Xi’an); BMS202 (HY-19745), STF62247 (HY-100746), 3-MA (HY-19312), and Chloroquine (HY-17589A) from MedChemExpress (Shanghai); ethanol from Guangzhou Chemical Reagent Factory. .. L

    CCK-8 Assay:

    Article Title: HIF-activated priming of TRAIL-induced cell death determines epigenetic vulnerability in kidney cancer
    Article Snippet: The percentage of PI-positive cells was quantified.The percentage of PI-positive cells was quantified.. To validate cell death inhibitors, RCC10 (1 × 10 5 cells/well) cells were seeded onto the 12-well plate for 12 h and pre-treated for 30 min with vehicle, Necrostatin-1 (10 μM), Ferrostatin-1 (2 μM), 3-MA (1.25 mM), or AC-FLTD-CMK (10 μM), followed by 3 days of co-treatment with vehicle or respective cell death activator, including Compound6i (0.5 μM, necroptosis activator, HY-144828, MCE), RSL3 (50 nM, ferroptosis activator, HY-100218A, MCE), STF-62247 (5 μM, autophagy inducer, HY-100746, MCE), or Nigericin (1 μM, pyroptosis inducer, HY-127019, MCE).. MDA-MB-231 (1 × 10 5 cells/well) cells were pre-treated for 30 min with vehicle or Olaparib (10 μM), followed by 15 min of co-treatment with vehicle or N-Methyl-N-nitroso-N′-nitroguanidine (MNNG, 50 μM, parthanatos inducer, N -12560, Chem Service).MDA-MB-231 (1 × 10 5 cells/well) cells were pre-treated for 30 min with vehicle or Olaparib (10 μM), followed by 15 min of co-treatment with vehicle or..

    Article Title: HIF-activated priming of TRAIL-induced cell death determines epigenetic vulnerability in kidney cancer.
    Article Snippet: ssue Kit Qiagen Cat# 69504 RNeasy mini kit Qiagen Cat# 74104 KAPA mRNA HyperPrep Kit Roche Cat# 08098123702 Bioactive Compound Library Selleckchem Cat# L1700 Chemicals and recombinant proteins SGI1027 MCE HY-13962 Necrostatin-1 MCE HY-15760 Ferrostatin-1 MCE HY-100579 Olaparib MCE HY-10162 Compound6i MCE HY-100218A STF-62247 MCE HY-100746 Nigericin MCE HY-127019 Decitabine MCE HY-A0004 N-Methyl-N-n

    Article Title: HIF-activated priming of TRAIL-induced cell death determines epigenetic vulnerability in kidney cancer.
    Article Snippet: The percentage of PI-positive cells was quantified.The percentage of PI-positive cells was quantified.. To validate cell death inhibitors, RCC10 (1 × 10 5 cells/well) cells were seeded onto the 12-well plate for 12 h and pre-treated for 30 min with vehicle, Necrostatin-1 (10 μM), Ferrostatin-1 (2 μM), 3-MA (1.25 mM), or AC-FLTD-CMK (10 μM), followed by 3 days of cotreatment with vehicle or respective cell death activator, including Compound6i (0.5 μM, necroptosis activator, HY-144828, MCE), RSL3 (50 nM, ferroptosis activator, HY-100218A, MCE), STF-62247 (5 μM, autophagy inducer, HY-100746, MCE), or Nigericin (1 μM, pyroptosis inducer, HY-127019, MCE).. MDA-MB-231 (1 × 10 5 cells/well) cells were pre-treated for 30 min with vehicle or Olaparib (10 μM), followed by 15 min of co-treatment with vehicle or N-Methyl-N-nitroso-N ′ -nitroguanidine (MNNG, 50 μM, parthanatos Cell Reports Medicine 7, 102630, March 17, 2026 e3 OPEN ACCESS inducer, N-12560, Chem Service).MDA-MB-231 (1 × 10 5 cells/well) cells were pre-treated for 30 min with vehicle or Olaparib (10 μM), followed by 15 min of co-treatment with vehicle or..

    Article Title: Autophagy-amplifying nanoparticles evoke immunogenic cell death combined with anti-PD-1/PD-L1 for residual tumors immunotherapy after RFA.
    Article Snippet: Zn (NO3)2•6H2O and 2-MeIM were purchased from Aladdin Holdings Group Co., Ltd (Shanghai); PEGFA 2000, ICG, and FITC from Rixi Biotechnology Co., Ltd. (Xi’an); BMS202 (HY-19745), STF62247 (HY100746), 3-MA (HY-19312), and Chloroquine (HY17589A) from MedChemExpress (Shanghai); ethanol from Guangzhou Chemical Reagent Factory.. LC3B antibody (L7543) was purchased from Sigma; ATG5 antibody (T55766) from Abmart; p-mTOR antibody (Ser172) (#2971S) from CST; HMGB1 antibody (10,829-1-AP) from Proteintech; HRP-Goat anti-rabbit IgG(H + L) (E030120-01) from Earthox; CD4 antibody (bs-0647R), CD8 antibody (bs-4791R) from Bioss;p62 antibody (ab109012), mTOR antibody (ab137133), Calreticulin antibody (ab92516), Ki67 antibody (ab16667), Goat anti-rabbit IgG H&L (Alexa Fluor® 488) (ab150077), Goat anti-rabbit IgG H&L (Alexa Fluor® 555) (ab150078), and DAPI Staining Solution (ab228549) from Abcam.LC3B antibody (L7543) was purchased from Sigma; ATG5 antibody (T55766) from Abmart; p-mTOR antibody (Ser172) (#2971S) from CST; HMGB1 antibody (10,829-1-AP) from Proteintech; HRP-Goat anti-rabbit IgG(H + L) (E030120-01) from Earthox; CD4 antibody (bs-0647R), CD8 antibody (bs-4791R) from Bioss;p62 antibody (ab109012), mTOR antibody (ab137133),..

    Article Title: Autophagy-amplifying nanoparticles evoke immunogenic cell death combined with anti-PD-1/PD-L1 for residual tumors immunotherapy after RFA
    Article Snippet: Zn (NO3)2•6H2O and 2-MeIM were purchased from Aladdin Holdings Group Co., Ltd (Shanghai); PEG-FA 2000, ICG, and FITC from Rixi Biotechnology Co., Ltd. (Xi’an); BMS202 (HY-19745), STF62247 (HY-100746), 3-MA (HY-19312), and Chloroquine (HY-17589A) from MedChemExpress (Shanghai); ethanol from Guangzhou Chemical Reagent Factory. .. L

    Double Staining:

    Article Title: HIF-activated priming of TRAIL-induced cell death determines epigenetic vulnerability in kidney cancer
    Article Snippet: The percentage of PI-positive cells was quantified.The percentage of PI-positive cells was quantified.. To validate cell death inhibitors, RCC10 (1 × 10 5 cells/well) cells were seeded onto the 12-well plate for 12 h and pre-treated for 30 min with vehicle, Necrostatin-1 (10 μM), Ferrostatin-1 (2 μM), 3-MA (1.25 mM), or AC-FLTD-CMK (10 μM), followed by 3 days of co-treatment with vehicle or respective cell death activator, including Compound6i (0.5 μM, necroptosis activator, HY-144828, MCE), RSL3 (50 nM, ferroptosis activator, HY-100218A, MCE), STF-62247 (5 μM, autophagy inducer, HY-100746, MCE), or Nigericin (1 μM, pyroptosis inducer, HY-127019, MCE).. MDA-MB-231 (1 × 10 5 cells/well) cells were pre-treated for 30 min with vehicle or Olaparib (10 μM), followed by 15 min of co-treatment with vehicle or N-Methyl-N-nitroso-N′-nitroguanidine (MNNG, 50 μM, parthanatos inducer, N -12560, Chem Service).MDA-MB-231 (1 × 10 5 cells/well) cells were pre-treated for 30 min with vehicle or Olaparib (10 μM), followed by 15 min of co-treatment with vehicle or..

    Article Title: HIF-activated priming of TRAIL-induced cell death determines epigenetic vulnerability in kidney cancer.
    Article Snippet: ssue Kit Qiagen Cat# 69504 RNeasy mini kit Qiagen Cat# 74104 KAPA mRNA HyperPrep Kit Roche Cat# 08098123702 Bioactive Compound Library Selleckchem Cat# L1700 Chemicals and recombinant proteins SGI1027 MCE HY-13962 Necrostatin-1 MCE HY-15760 Ferrostatin-1 MCE HY-100579 Olaparib MCE HY-10162 Compound6i MCE HY-100218A STF-62247 MCE HY-100746 Nigericin MCE HY-127019 Decitabine MCE HY-A0004 N-Methyl-N-n

    Article Title: HIF-activated priming of TRAIL-induced cell death determines epigenetic vulnerability in kidney cancer.
    Article Snippet: The percentage of PI-positive cells was quantified.The percentage of PI-positive cells was quantified.. To validate cell death inhibitors, RCC10 (1 × 10 5 cells/well) cells were seeded onto the 12-well plate for 12 h and pre-treated for 30 min with vehicle, Necrostatin-1 (10 μM), Ferrostatin-1 (2 μM), 3-MA (1.25 mM), or AC-FLTD-CMK (10 μM), followed by 3 days of cotreatment with vehicle or respective cell death activator, including Compound6i (0.5 μM, necroptosis activator, HY-144828, MCE), RSL3 (50 nM, ferroptosis activator, HY-100218A, MCE), STF-62247 (5 μM, autophagy inducer, HY-100746, MCE), or Nigericin (1 μM, pyroptosis inducer, HY-127019, MCE).. MDA-MB-231 (1 × 10 5 cells/well) cells were pre-treated for 30 min with vehicle or Olaparib (10 μM), followed by 15 min of co-treatment with vehicle or N-Methyl-N-nitroso-N ′ -nitroguanidine (MNNG, 50 μM, parthanatos Cell Reports Medicine 7, 102630, March 17, 2026 e3 OPEN ACCESS inducer, N-12560, Chem Service).MDA-MB-231 (1 × 10 5 cells/well) cells were pre-treated for 30 min with vehicle or Olaparib (10 μM), followed by 15 min of co-treatment with vehicle or..

    Article Title: Autophagy-amplifying nanoparticles evoke immunogenic cell death combined with anti-PD-1/PD-L1 for residual tumors immunotherapy after RFA.
    Article Snippet: Zn (NO3)2•6H2O and 2-MeIM were purchased from Aladdin Holdings Group Co., Ltd (Shanghai); PEGFA 2000, ICG, and FITC from Rixi Biotechnology Co., Ltd. (Xi’an); BMS202 (HY-19745), STF62247 (HY100746), 3-MA (HY-19312), and Chloroquine (HY17589A) from MedChemExpress (Shanghai); ethanol from Guangzhou Chemical Reagent Factory.. LC3B antibody (L7543) was purchased from Sigma; ATG5 antibody (T55766) from Abmart; p-mTOR antibody (Ser172) (#2971S) from CST; HMGB1 antibody (10,829-1-AP) from Proteintech; HRP-Goat anti-rabbit IgG(H + L) (E030120-01) from Earthox; CD4 antibody (bs-0647R), CD8 antibody (bs-4791R) from Bioss;p62 antibody (ab109012), mTOR antibody (ab137133), Calreticulin antibody (ab92516), Ki67 antibody (ab16667), Goat anti-rabbit IgG H&L (Alexa Fluor® 488) (ab150077), Goat anti-rabbit IgG H&L (Alexa Fluor® 555) (ab150078), and DAPI Staining Solution (ab228549) from Abcam.LC3B antibody (L7543) was purchased from Sigma; ATG5 antibody (T55766) from Abmart; p-mTOR antibody (Ser172) (#2971S) from CST; HMGB1 antibody (10,829-1-AP) from Proteintech; HRP-Goat anti-rabbit IgG(H + L) (E030120-01) from Earthox; CD4 antibody (bs-0647R), CD8 antibody (bs-4791R) from Bioss;p62 antibody (ab109012), mTOR antibody (ab137133),..

    Article Title: Autophagy-amplifying nanoparticles evoke immunogenic cell death combined with anti-PD-1/PD-L1 for residual tumors immunotherapy after RFA
    Article Snippet: Zn (NO3)2•6H2O and 2-MeIM were purchased from Aladdin Holdings Group Co., Ltd (Shanghai); PEG-FA 2000, ICG, and FITC from Rixi Biotechnology Co., Ltd. (Xi’an); BMS202 (HY-19745), STF62247 (HY-100746), 3-MA (HY-19312), and Chloroquine (HY-17589A) from MedChemExpress (Shanghai); ethanol from Guangzhou Chemical Reagent Factory. .. L

    Flow Cytometry:

    Article Title: HIF-activated priming of TRAIL-induced cell death determines epigenetic vulnerability in kidney cancer
    Article Snippet: The percentage of PI-positive cells was quantified.The percentage of PI-positive cells was quantified.. To validate cell death inhibitors, RCC10 (1 × 10 5 cells/well) cells were seeded onto the 12-well plate for 12 h and pre-treated for 30 min with vehicle, Necrostatin-1 (10 μM), Ferrostatin-1 (2 μM), 3-MA (1.25 mM), or AC-FLTD-CMK (10 μM), followed by 3 days of co-treatment with vehicle or respective cell death activator, including Compound6i (0.5 μM, necroptosis activator, HY-144828, MCE), RSL3 (50 nM, ferroptosis activator, HY-100218A, MCE), STF-62247 (5 μM, autophagy inducer, HY-100746, MCE), or Nigericin (1 μM, pyroptosis inducer, HY-127019, MCE).. MDA-MB-231 (1 × 10 5 cells/well) cells were pre-treated for 30 min with vehicle or Olaparib (10 μM), followed by 15 min of co-treatment with vehicle or N-Methyl-N-nitroso-N′-nitroguanidine (MNNG, 50 μM, parthanatos inducer, N -12560, Chem Service).MDA-MB-231 (1 × 10 5 cells/well) cells were pre-treated for 30 min with vehicle or Olaparib (10 μM), followed by 15 min of co-treatment with vehicle or..

    Article Title: HIF-activated priming of TRAIL-induced cell death determines epigenetic vulnerability in kidney cancer.
    Article Snippet: ssue Kit Qiagen Cat# 69504 RNeasy mini kit Qiagen Cat# 74104 KAPA mRNA HyperPrep Kit Roche Cat# 08098123702 Bioactive Compound Library Selleckchem Cat# L1700 Chemicals and recombinant proteins SGI1027 MCE HY-13962 Necrostatin-1 MCE HY-15760 Ferrostatin-1 MCE HY-100579 Olaparib MCE HY-10162 Compound6i MCE HY-100218A STF-62247 MCE HY-100746 Nigericin MCE HY-127019 Decitabine MCE HY-A0004 N-Methyl-N-n

    Article Title: HIF-activated priming of TRAIL-induced cell death determines epigenetic vulnerability in kidney cancer.
    Article Snippet: The percentage of PI-positive cells was quantified.The percentage of PI-positive cells was quantified.. To validate cell death inhibitors, RCC10 (1 × 10 5 cells/well) cells were seeded onto the 12-well plate for 12 h and pre-treated for 30 min with vehicle, Necrostatin-1 (10 μM), Ferrostatin-1 (2 μM), 3-MA (1.25 mM), or AC-FLTD-CMK (10 μM), followed by 3 days of cotreatment with vehicle or respective cell death activator, including Compound6i (0.5 μM, necroptosis activator, HY-144828, MCE), RSL3 (50 nM, ferroptosis activator, HY-100218A, MCE), STF-62247 (5 μM, autophagy inducer, HY-100746, MCE), or Nigericin (1 μM, pyroptosis inducer, HY-127019, MCE).. MDA-MB-231 (1 × 10 5 cells/well) cells were pre-treated for 30 min with vehicle or Olaparib (10 μM), followed by 15 min of co-treatment with vehicle or N-Methyl-N-nitroso-N ′ -nitroguanidine (MNNG, 50 μM, parthanatos Cell Reports Medicine 7, 102630, March 17, 2026 e3 OPEN ACCESS inducer, N-12560, Chem Service).MDA-MB-231 (1 × 10 5 cells/well) cells were pre-treated for 30 min with vehicle or Olaparib (10 μM), followed by 15 min of co-treatment with vehicle or..

    Article Title: Autophagy-amplifying nanoparticles evoke immunogenic cell death combined with anti-PD-1/PD-L1 for residual tumors immunotherapy after RFA.
    Article Snippet: Zn (NO3)2•6H2O and 2-MeIM were purchased from Aladdin Holdings Group Co., Ltd (Shanghai); PEGFA 2000, ICG, and FITC from Rixi Biotechnology Co., Ltd. (Xi’an); BMS202 (HY-19745), STF62247 (HY100746), 3-MA (HY-19312), and Chloroquine (HY17589A) from MedChemExpress (Shanghai); ethanol from Guangzhou Chemical Reagent Factory.. LC3B antibody (L7543) was purchased from Sigma; ATG5 antibody (T55766) from Abmart; p-mTOR antibody (Ser172) (#2971S) from CST; HMGB1 antibody (10,829-1-AP) from Proteintech; HRP-Goat anti-rabbit IgG(H + L) (E030120-01) from Earthox; CD4 antibody (bs-0647R), CD8 antibody (bs-4791R) from Bioss;p62 antibody (ab109012), mTOR antibody (ab137133), Calreticulin antibody (ab92516), Ki67 antibody (ab16667), Goat anti-rabbit IgG H&L (Alexa Fluor® 488) (ab150077), Goat anti-rabbit IgG H&L (Alexa Fluor® 555) (ab150078), and DAPI Staining Solution (ab228549) from Abcam.LC3B antibody (L7543) was purchased from Sigma; ATG5 antibody (T55766) from Abmart; p-mTOR antibody (Ser172) (#2971S) from CST; HMGB1 antibody (10,829-1-AP) from Proteintech; HRP-Goat anti-rabbit IgG(H + L) (E030120-01) from Earthox; CD4 antibody (bs-0647R), CD8 antibody (bs-4791R) from Bioss;p62 antibody (ab109012), mTOR antibody (ab137133),..

    Article Title: Autophagy-amplifying nanoparticles evoke immunogenic cell death combined with anti-PD-1/PD-L1 for residual tumors immunotherapy after RFA
    Article Snippet: Zn (NO3)2•6H2O and 2-MeIM were purchased from Aladdin Holdings Group Co., Ltd (Shanghai); PEG-FA 2000, ICG, and FITC from Rixi Biotechnology Co., Ltd. (Xi’an); BMS202 (HY-19745), STF62247 (HY-100746), 3-MA (HY-19312), and Chloroquine (HY-17589A) from MedChemExpress (Shanghai); ethanol from Guangzhou Chemical Reagent Factory. .. L

    Concentration Assay:

    Article Title: HIF-activated priming of TRAIL-induced cell death determines epigenetic vulnerability in kidney cancer
    Article Snippet: The percentage of PI-positive cells was quantified.The percentage of PI-positive cells was quantified.. To validate cell death inhibitors, RCC10 (1 × 10 5 cells/well) cells were seeded onto the 12-well plate for 12 h and pre-treated for 30 min with vehicle, Necrostatin-1 (10 μM), Ferrostatin-1 (2 μM), 3-MA (1.25 mM), or AC-FLTD-CMK (10 μM), followed by 3 days of co-treatment with vehicle or respective cell death activator, including Compound6i (0.5 μM, necroptosis activator, HY-144828, MCE), RSL3 (50 nM, ferroptosis activator, HY-100218A, MCE), STF-62247 (5 μM, autophagy inducer, HY-100746, MCE), or Nigericin (1 μM, pyroptosis inducer, HY-127019, MCE).. MDA-MB-231 (1 × 10 5 cells/well) cells were pre-treated for 30 min with vehicle or Olaparib (10 μM), followed by 15 min of co-treatment with vehicle or N-Methyl-N-nitroso-N′-nitroguanidine (MNNG, 50 μM, parthanatos inducer, N -12560, Chem Service).MDA-MB-231 (1 × 10 5 cells/well) cells were pre-treated for 30 min with vehicle or Olaparib (10 μM), followed by 15 min of co-treatment with vehicle or..

    Article Title: HIF-activated priming of TRAIL-induced cell death determines epigenetic vulnerability in kidney cancer.
    Article Snippet: ssue Kit Qiagen Cat# 69504 RNeasy mini kit Qiagen Cat# 74104 KAPA mRNA HyperPrep Kit Roche Cat# 08098123702 Bioactive Compound Library Selleckchem Cat# L1700 Chemicals and recombinant proteins SGI1027 MCE HY-13962 Necrostatin-1 MCE HY-15760 Ferrostatin-1 MCE HY-100579 Olaparib MCE HY-10162 Compound6i MCE HY-100218A STF-62247 MCE HY-100746 Nigericin MCE HY-127019 Decitabine MCE HY-A0004 N-Methyl-N-n

    Article Title: HIF-activated priming of TRAIL-induced cell death determines epigenetic vulnerability in kidney cancer.
    Article Snippet: The percentage of PI-positive cells was quantified.The percentage of PI-positive cells was quantified.. To validate cell death inhibitors, RCC10 (1 × 10 5 cells/well) cells were seeded onto the 12-well plate for 12 h and pre-treated for 30 min with vehicle, Necrostatin-1 (10 μM), Ferrostatin-1 (2 μM), 3-MA (1.25 mM), or AC-FLTD-CMK (10 μM), followed by 3 days of cotreatment with vehicle or respective cell death activator, including Compound6i (0.5 μM, necroptosis activator, HY-144828, MCE), RSL3 (50 nM, ferroptosis activator, HY-100218A, MCE), STF-62247 (5 μM, autophagy inducer, HY-100746, MCE), or Nigericin (1 μM, pyroptosis inducer, HY-127019, MCE).. MDA-MB-231 (1 × 10 5 cells/well) cells were pre-treated for 30 min with vehicle or Olaparib (10 μM), followed by 15 min of co-treatment with vehicle or N-Methyl-N-nitroso-N ′ -nitroguanidine (MNNG, 50 μM, parthanatos Cell Reports Medicine 7, 102630, March 17, 2026 e3 OPEN ACCESS inducer, N-12560, Chem Service).MDA-MB-231 (1 × 10 5 cells/well) cells were pre-treated for 30 min with vehicle or Olaparib (10 μM), followed by 15 min of co-treatment with vehicle or..

    Article Title: Autophagy-amplifying nanoparticles evoke immunogenic cell death combined with anti-PD-1/PD-L1 for residual tumors immunotherapy after RFA.
    Article Snippet: Zn (NO3)2•6H2O and 2-MeIM were purchased from Aladdin Holdings Group Co., Ltd (Shanghai); PEGFA 2000, ICG, and FITC from Rixi Biotechnology Co., Ltd. (Xi’an); BMS202 (HY-19745), STF62247 (HY100746), 3-MA (HY-19312), and Chloroquine (HY17589A) from MedChemExpress (Shanghai); ethanol from Guangzhou Chemical Reagent Factory.. LC3B antibody (L7543) was purchased from Sigma; ATG5 antibody (T55766) from Abmart; p-mTOR antibody (Ser172) (#2971S) from CST; HMGB1 antibody (10,829-1-AP) from Proteintech; HRP-Goat anti-rabbit IgG(H + L) (E030120-01) from Earthox; CD4 antibody (bs-0647R), CD8 antibody (bs-4791R) from Bioss;p62 antibody (ab109012), mTOR antibody (ab137133), Calreticulin antibody (ab92516), Ki67 antibody (ab16667), Goat anti-rabbit IgG H&L (Alexa Fluor® 488) (ab150077), Goat anti-rabbit IgG H&L (Alexa Fluor® 555) (ab150078), and DAPI Staining Solution (ab228549) from Abcam.LC3B antibody (L7543) was purchased from Sigma; ATG5 antibody (T55766) from Abmart; p-mTOR antibody (Ser172) (#2971S) from CST; HMGB1 antibody (10,829-1-AP) from Proteintech; HRP-Goat anti-rabbit IgG(H + L) (E030120-01) from Earthox; CD4 antibody (bs-0647R), CD8 antibody (bs-4791R) from Bioss;p62 antibody (ab109012), mTOR antibody (ab137133),..

    Article Title: Autophagy-amplifying nanoparticles evoke immunogenic cell death combined with anti-PD-1/PD-L1 for residual tumors immunotherapy after RFA
    Article Snippet: Zn (NO3)2•6H2O and 2-MeIM were purchased from Aladdin Holdings Group Co., Ltd (Shanghai); PEG-FA 2000, ICG, and FITC from Rixi Biotechnology Co., Ltd. (Xi’an); BMS202 (HY-19745), STF62247 (HY-100746), 3-MA (HY-19312), and Chloroquine (HY-17589A) from MedChemExpress (Shanghai); ethanol from Guangzhou Chemical Reagent Factory. .. L



    Similar Products

    95
    MedChemExpress stf 083010
    (A) Schematic of the workflow for comparative proteomic analysis of denuded excellent-grade and poor-grade goat oocytes, including protein extraction, LC–MS/MS analysis, and downstream protein profiling. (B) Venn diagram showing the overlap between proteins identified in excellent-grade and poor-grade oocytes. (C) Principal component analysis (PCA) showing separation of the proteomic profiles of excellent-grade and poor-grade oocytes. (D) Partial least squares discriminant analysis (PLS-DA) score plot illustrating differences in protein profiles between the two groups. (E) Heatmap showing the relative abundance of differentially abundant proteins in excellent-grade and poor-grade oocytes. (F,G) Gene Ontology (GO) enrichment analysis of differentially abundant proteins associated with cellular components (F) and biological processes (G). Blue bars indicate proteins upregulated in poor-grade oocytes, whereas red bars indicate proteins downregulated in poor-grade oocytes. (H) Volcano plot showing differential protein abundance between excellent-grade and poor-grade oocytes, highlighting significantly altered proteins, including IRE1α. (I–K) RT-qPCR analysis of ER stress-associated transcripts in excellent-grade and poor-grade oocytes: (I) the ratio of spliced to unspliced XBP1 mRNA (XBP1s/XBP1u), (J) relative ATF6 mRNA expression, and (K) relative IRE1α (ERN1) mRNA expression. Each group comprised 250 oocytes. (L) Schematic of the experimental design used to assess meiotic maturation following treatment with tunicamycin ™ in excellent-grade oocytes, or tauroursodeoxycholic acid (TUDCA) and the IRE1α <t>inhibitor</t> <t>STF-083010</t> (STF) in poor-grade oocytes, during in vitro maturation (IVM). (M–O) Quantification of the proportion of oocytes reaching metaphase II (MII) following pharmacological manipulation of ER stress signaling: (M) excellent-grade oocytes treated with or without TM; (N) poor-grade oocytes treated with or without STF; and (O) poor-grade oocytes treated with or without TUDCA. The numbers of oocytes analyzed are indicated above the bars. (P) Predicted secondary structure of QPRT mRNA showing a candidate stem– loop region containing a CUG motif. This computational prediction identifies a potential RNA structural feature for further investigation. (Q) Relative QPRT mRNA expression in excellent-grade oocytes and excellent-grade oocytes treated with TM, assessed by RT-qPCR. ® Relative QPRT mRNA expression in poor-grade oocytes following TUDCA treatment. (S) Relative IRE1α ( ERN1 ) mRNA expression in poor-grade oocytes following TUDCA treatment. (T) Schematic of the in vitro transcription and preparation of QPRT RNA substrates for the IRE1α-mediated RNA cleavage assay. (U) Representative RNA cleavage assay showing QPRT RNA incubated under the indicated conditions, including recombinant IRE1α. The accompanying table lists the sizes of the detected RNA products. (V) Schematic of the experimental workflow for assessing QPRT mRNA stability in excellent-grade and poor-grade oocytes following actinomycin D treatment to inhibit new transcription. (W) Relative QPRT mRNA abundance in excellent-grade and poor-grade oocytes at 0 and 3 h following actinomycin D treatment, assessed by RT-qPCR. Values are expressed relative to the corresponding 0-hr level. The number of oocytes analyzed is indicated above each graph. Data are presented as mean ± SEM. Statistical significance is indicated by asterisks (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Statistical significance was assessed using unpaired t-test and ordinary one-way ANOVA (N and O) and 2way ANOVA (W).
    Stf 083010, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/stf/STF-083010/bio_rxiv__64898__2026__11__04__764453-421-0-2
    Average 95 stars, based on 1 article reviews
    stf 083010 - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    95
    MedChemExpress stf-083010
    (A) Schematic of the workflow for comparative proteomic analysis of denuded excellent-grade and poor-grade goat oocytes, including protein extraction, LC–MS/MS analysis, and downstream protein profiling. (B) Venn diagram showing the overlap between proteins identified in excellent-grade and poor-grade oocytes. (C) Principal component analysis (PCA) showing separation of the proteomic profiles of excellent-grade and poor-grade oocytes. (D) Partial least squares discriminant analysis (PLS-DA) score plot illustrating differences in protein profiles between the two groups. (E) Heatmap showing the relative abundance of differentially abundant proteins in excellent-grade and poor-grade oocytes. (F,G) Gene Ontology (GO) enrichment analysis of differentially abundant proteins associated with cellular components (F) and biological processes (G). Blue bars indicate proteins upregulated in poor-grade oocytes, whereas red bars indicate proteins downregulated in poor-grade oocytes. (H) Volcano plot showing differential protein abundance between excellent-grade and poor-grade oocytes, highlighting significantly altered proteins, including IRE1α. (I–K) RT-qPCR analysis of ER stress-associated transcripts in excellent-grade and poor-grade oocytes: (I) the ratio of spliced to unspliced XBP1 mRNA (XBP1s/XBP1u), (J) relative ATF6 mRNA expression, and (K) relative IRE1α (ERN1) mRNA expression. Each group comprised 250 oocytes. (L) Schematic of the experimental design used to assess meiotic maturation following treatment with tunicamycin ™ in excellent-grade oocytes, or tauroursodeoxycholic acid (TUDCA) and the IRE1α <t>inhibitor</t> <t>STF-083010</t> (STF) in poor-grade oocytes, during in vitro maturation (IVM). (M–O) Quantification of the proportion of oocytes reaching metaphase II (MII) following pharmacological manipulation of ER stress signaling: (M) excellent-grade oocytes treated with or without TM; (N) poor-grade oocytes treated with or without STF; and (O) poor-grade oocytes treated with or without TUDCA. The numbers of oocytes analyzed are indicated above the bars. (P) Predicted secondary structure of QPRT mRNA showing a candidate stem– loop region containing a CUG motif. This computational prediction identifies a potential RNA structural feature for further investigation. (Q) Relative QPRT mRNA expression in excellent-grade oocytes and excellent-grade oocytes treated with TM, assessed by RT-qPCR. ® Relative QPRT mRNA expression in poor-grade oocytes following TUDCA treatment. (S) Relative IRE1α ( ERN1 ) mRNA expression in poor-grade oocytes following TUDCA treatment. (T) Schematic of the in vitro transcription and preparation of QPRT RNA substrates for the IRE1α-mediated RNA cleavage assay. (U) Representative RNA cleavage assay showing QPRT RNA incubated under the indicated conditions, including recombinant IRE1α. The accompanying table lists the sizes of the detected RNA products. (V) Schematic of the experimental workflow for assessing QPRT mRNA stability in excellent-grade and poor-grade oocytes following actinomycin D treatment to inhibit new transcription. (W) Relative QPRT mRNA abundance in excellent-grade and poor-grade oocytes at 0 and 3 h following actinomycin D treatment, assessed by RT-qPCR. Values are expressed relative to the corresponding 0-hr level. The number of oocytes analyzed is indicated above each graph. Data are presented as mean ± SEM. Statistical significance is indicated by asterisks (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Statistical significance was assessed using unpaired t-test and ordinary one-way ANOVA (N and O) and 2way ANOVA (W).
    Stf 083010, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/stf/STF-083010/custom%40hy-15845%4042961638
    Average 95 stars, based on 1 article reviews
    stf-083010 - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    94
    MedChemExpress dmso
    (A) Schematic of the workflow for comparative proteomic analysis of denuded excellent-grade and poor-grade goat oocytes, including protein extraction, LC–MS/MS analysis, and downstream protein profiling. (B) Venn diagram showing the overlap between proteins identified in excellent-grade and poor-grade oocytes. (C) Principal component analysis (PCA) showing separation of the proteomic profiles of excellent-grade and poor-grade oocytes. (D) Partial least squares discriminant analysis (PLS-DA) score plot illustrating differences in protein profiles between the two groups. (E) Heatmap showing the relative abundance of differentially abundant proteins in excellent-grade and poor-grade oocytes. (F,G) Gene Ontology (GO) enrichment analysis of differentially abundant proteins associated with cellular components (F) and biological processes (G). Blue bars indicate proteins upregulated in poor-grade oocytes, whereas red bars indicate proteins downregulated in poor-grade oocytes. (H) Volcano plot showing differential protein abundance between excellent-grade and poor-grade oocytes, highlighting significantly altered proteins, including IRE1α. (I–K) RT-qPCR analysis of ER stress-associated transcripts in excellent-grade and poor-grade oocytes: (I) the ratio of spliced to unspliced XBP1 mRNA (XBP1s/XBP1u), (J) relative ATF6 mRNA expression, and (K) relative IRE1α (ERN1) mRNA expression. Each group comprised 250 oocytes. (L) Schematic of the experimental design used to assess meiotic maturation following treatment with tunicamycin ™ in excellent-grade oocytes, or tauroursodeoxycholic acid (TUDCA) and the IRE1α <t>inhibitor</t> <t>STF-083010</t> (STF) in poor-grade oocytes, during in vitro maturation (IVM). (M–O) Quantification of the proportion of oocytes reaching metaphase II (MII) following pharmacological manipulation of ER stress signaling: (M) excellent-grade oocytes treated with or without TM; (N) poor-grade oocytes treated with or without STF; and (O) poor-grade oocytes treated with or without TUDCA. The numbers of oocytes analyzed are indicated above the bars. (P) Predicted secondary structure of QPRT mRNA showing a candidate stem– loop region containing a CUG motif. This computational prediction identifies a potential RNA structural feature for further investigation. (Q) Relative QPRT mRNA expression in excellent-grade oocytes and excellent-grade oocytes treated with TM, assessed by RT-qPCR. ® Relative QPRT mRNA expression in poor-grade oocytes following TUDCA treatment. (S) Relative IRE1α ( ERN1 ) mRNA expression in poor-grade oocytes following TUDCA treatment. (T) Schematic of the in vitro transcription and preparation of QPRT RNA substrates for the IRE1α-mediated RNA cleavage assay. (U) Representative RNA cleavage assay showing QPRT RNA incubated under the indicated conditions, including recombinant IRE1α. The accompanying table lists the sizes of the detected RNA products. (V) Schematic of the experimental workflow for assessing QPRT mRNA stability in excellent-grade and poor-grade oocytes following actinomycin D treatment to inhibit new transcription. (W) Relative QPRT mRNA abundance in excellent-grade and poor-grade oocytes at 0 and 3 h following actinomycin D treatment, assessed by RT-qPCR. Values are expressed relative to the corresponding 0-hr level. The number of oocytes analyzed is indicated above each graph. Data are presented as mean ± SEM. Statistical significance is indicated by asterisks (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Statistical significance was assessed using unpaired t-test and ordinary one-way ANOVA (N and O) and 2way ANOVA (W).
    Dmso, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/stf/STF-118804/bio_rxiv__64898__2026__10__26__761924-227-2-7
    Average 94 stars, based on 1 article reviews
    dmso - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    95
    MedChemExpress stf083010
    (A) Schematic of the workflow for comparative proteomic analysis of denuded excellent-grade and poor-grade goat oocytes, including protein extraction, LC–MS/MS analysis, and downstream protein profiling. (B) Venn diagram showing the overlap between proteins identified in excellent-grade and poor-grade oocytes. (C) Principal component analysis (PCA) showing separation of the proteomic profiles of excellent-grade and poor-grade oocytes. (D) Partial least squares discriminant analysis (PLS-DA) score plot illustrating differences in protein profiles between the two groups. (E) Heatmap showing the relative abundance of differentially abundant proteins in excellent-grade and poor-grade oocytes. (F,G) Gene Ontology (GO) enrichment analysis of differentially abundant proteins associated with cellular components (F) and biological processes (G). Blue bars indicate proteins upregulated in poor-grade oocytes, whereas red bars indicate proteins downregulated in poor-grade oocytes. (H) Volcano plot showing differential protein abundance between excellent-grade and poor-grade oocytes, highlighting significantly altered proteins, including IRE1α. (I–K) RT-qPCR analysis of ER stress-associated transcripts in excellent-grade and poor-grade oocytes: (I) the ratio of spliced to unspliced XBP1 mRNA (XBP1s/XBP1u), (J) relative ATF6 mRNA expression, and (K) relative IRE1α (ERN1) mRNA expression. Each group comprised 250 oocytes. (L) Schematic of the experimental design used to assess meiotic maturation following treatment with tunicamycin ™ in excellent-grade oocytes, or tauroursodeoxycholic acid (TUDCA) and the IRE1α <t>inhibitor</t> <t>STF-083010</t> (STF) in poor-grade oocytes, during in vitro maturation (IVM). (M–O) Quantification of the proportion of oocytes reaching metaphase II (MII) following pharmacological manipulation of ER stress signaling: (M) excellent-grade oocytes treated with or without TM; (N) poor-grade oocytes treated with or without STF; and (O) poor-grade oocytes treated with or without TUDCA. The numbers of oocytes analyzed are indicated above the bars. (P) Predicted secondary structure of QPRT mRNA showing a candidate stem– loop region containing a CUG motif. This computational prediction identifies a potential RNA structural feature for further investigation. (Q) Relative QPRT mRNA expression in excellent-grade oocytes and excellent-grade oocytes treated with TM, assessed by RT-qPCR. ® Relative QPRT mRNA expression in poor-grade oocytes following TUDCA treatment. (S) Relative IRE1α ( ERN1 ) mRNA expression in poor-grade oocytes following TUDCA treatment. (T) Schematic of the in vitro transcription and preparation of QPRT RNA substrates for the IRE1α-mediated RNA cleavage assay. (U) Representative RNA cleavage assay showing QPRT RNA incubated under the indicated conditions, including recombinant IRE1α. The accompanying table lists the sizes of the detected RNA products. (V) Schematic of the experimental workflow for assessing QPRT mRNA stability in excellent-grade and poor-grade oocytes following actinomycin D treatment to inhibit new transcription. (W) Relative QPRT mRNA abundance in excellent-grade and poor-grade oocytes at 0 and 3 h following actinomycin D treatment, assessed by RT-qPCR. Values are expressed relative to the corresponding 0-hr level. The number of oocytes analyzed is indicated above each graph. Data are presented as mean ± SEM. Statistical significance is indicated by asterisks (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Statistical significance was assessed using unpaired t-test and ordinary one-way ANOVA (N and O) and 2way ANOVA (W).
    Stf083010, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/stf/STF-083010/10__1007_slash_s00018___026___06389___6-38-4-5
    Average 95 stars, based on 1 article reviews
    stf083010 - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    95
    MedChemExpress ire1 inhibitor stf 083010
    (A) Schematic of the workflow for comparative proteomic analysis of denuded excellent-grade and poor-grade goat oocytes, including protein extraction, LC–MS/MS analysis, and downstream protein profiling. (B) Venn diagram showing the overlap between proteins identified in excellent-grade and poor-grade oocytes. (C) Principal component analysis (PCA) showing separation of the proteomic profiles of excellent-grade and poor-grade oocytes. (D) Partial least squares discriminant analysis (PLS-DA) score plot illustrating differences in protein profiles between the two groups. (E) Heatmap showing the relative abundance of differentially abundant proteins in excellent-grade and poor-grade oocytes. (F,G) Gene Ontology (GO) enrichment analysis of differentially abundant proteins associated with cellular components (F) and biological processes (G). Blue bars indicate proteins upregulated in poor-grade oocytes, whereas red bars indicate proteins downregulated in poor-grade oocytes. (H) Volcano plot showing differential protein abundance between excellent-grade and poor-grade oocytes, highlighting significantly altered proteins, including IRE1α. (I–K) RT-qPCR analysis of ER stress-associated transcripts in excellent-grade and poor-grade oocytes: (I) the ratio of spliced to unspliced XBP1 mRNA (XBP1s/XBP1u), (J) relative ATF6 mRNA expression, and (K) relative IRE1α (ERN1) mRNA expression. Each group comprised 250 oocytes. (L) Schematic of the experimental design used to assess meiotic maturation following treatment with tunicamycin ™ in excellent-grade oocytes, or tauroursodeoxycholic acid (TUDCA) and the IRE1α <t>inhibitor</t> <t>STF-083010</t> (STF) in poor-grade oocytes, during in vitro maturation (IVM). (M–O) Quantification of the proportion of oocytes reaching metaphase II (MII) following pharmacological manipulation of ER stress signaling: (M) excellent-grade oocytes treated with or without TM; (N) poor-grade oocytes treated with or without STF; and (O) poor-grade oocytes treated with or without TUDCA. The numbers of oocytes analyzed are indicated above the bars. (P) Predicted secondary structure of QPRT mRNA showing a candidate stem– loop region containing a CUG motif. This computational prediction identifies a potential RNA structural feature for further investigation. (Q) Relative QPRT mRNA expression in excellent-grade oocytes and excellent-grade oocytes treated with TM, assessed by RT-qPCR. ® Relative QPRT mRNA expression in poor-grade oocytes following TUDCA treatment. (S) Relative IRE1α ( ERN1 ) mRNA expression in poor-grade oocytes following TUDCA treatment. (T) Schematic of the in vitro transcription and preparation of QPRT RNA substrates for the IRE1α-mediated RNA cleavage assay. (U) Representative RNA cleavage assay showing QPRT RNA incubated under the indicated conditions, including recombinant IRE1α. The accompanying table lists the sizes of the detected RNA products. (V) Schematic of the experimental workflow for assessing QPRT mRNA stability in excellent-grade and poor-grade oocytes following actinomycin D treatment to inhibit new transcription. (W) Relative QPRT mRNA abundance in excellent-grade and poor-grade oocytes at 0 and 3 h following actinomycin D treatment, assessed by RT-qPCR. Values are expressed relative to the corresponding 0-hr level. The number of oocytes analyzed is indicated above each graph. Data are presented as mean ± SEM. Statistical significance is indicated by asterisks (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Statistical significance was assessed using unpaired t-test and ordinary one-way ANOVA (N and O) and 2way ANOVA (W).
    Ire1 Inhibitor Stf 083010, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/stf/STF-083010/10__1038_slash_s41598___026___64991___x-49-11-16
    Average 95 stars, based on 1 article reviews
    ire1 inhibitor stf 083010 - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    94
    MedChemExpress stf 31
    Characterization of DI/Ce6 and DI/Ce6@STF. (A, B) Representative electron microscopy images of DI/Ce6 and DI/Ce6@STF, respectively (scale bar: 100 nm); (C) Zeta potential of DI/Ce6 and DI/Ce6@STF; (D, E) Hydrodynamic particle size distributions of DI/Ce6 and DI/Ce6@STF measured by dynamic light scattering; (F) Particle size stability of DI/Ce6 and DI/Ce6@STF in PBS over 7 days; (G, H) Release Curves of DIABZI <t>and</t> <t>STF-31</t> in DI/Ce6@STF; (I) Comparison of HPLC chromatograms for DI/Ce6@STF nanoparticles and free drug.
    Stf 31, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/stf/STF-31/pmc13067122-183-0-10
    Average 94 stars, based on 1 article reviews
    stf 31 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    MedChemExpress stf
    Characterization of DI/Ce6 and DI/Ce6@STF. (A, B) Representative electron microscopy images of DI/Ce6 and DI/Ce6@STF, respectively (scale bar: 100 nm); (C) Zeta potential of DI/Ce6 and DI/Ce6@STF; (D, E) Hydrodynamic particle size distributions of DI/Ce6 and DI/Ce6@STF measured by dynamic light scattering; (F) Particle size stability of DI/Ce6 and DI/Ce6@STF in PBS over 7 days; (G, H) Release Curves of DIABZI <t>and</t> <t>STF-31</t> in DI/Ce6@STF; (I) Comparison of HPLC chromatograms for DI/Ce6@STF nanoparticles and free drug.
    Stf, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/stf/STF-118804/pm42018568-65-9-13
    Average 94 stars, based on 1 article reviews
    stf - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    95
    MedChemExpress csr ixa4
    Characterization of DI/Ce6 and DI/Ce6@STF. (A, B) Representative electron microscopy images of DI/Ce6 and DI/Ce6@STF, respectively (scale bar: 100 nm); (C) Zeta potential of DI/Ce6 and DI/Ce6@STF; (D, E) Hydrodynamic particle size distributions of DI/Ce6 and DI/Ce6@STF measured by dynamic light scattering; (F) Particle size stability of DI/Ce6 and DI/Ce6@STF in PBS over 7 days; (G, H) Release Curves of DIABZI <t>and</t> <t>STF-31</t> in DI/Ce6@STF; (I) Comparison of HPLC chromatograms for DI/Ce6@STF nanoparticles and free drug.
    Csr Ixa4, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/stf/STF-083010/pm41990753-36-24-38
    Average 95 stars, based on 1 article reviews
    csr ixa4 - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    Image Search Results


    (A) Schematic of the workflow for comparative proteomic analysis of denuded excellent-grade and poor-grade goat oocytes, including protein extraction, LC–MS/MS analysis, and downstream protein profiling. (B) Venn diagram showing the overlap between proteins identified in excellent-grade and poor-grade oocytes. (C) Principal component analysis (PCA) showing separation of the proteomic profiles of excellent-grade and poor-grade oocytes. (D) Partial least squares discriminant analysis (PLS-DA) score plot illustrating differences in protein profiles between the two groups. (E) Heatmap showing the relative abundance of differentially abundant proteins in excellent-grade and poor-grade oocytes. (F,G) Gene Ontology (GO) enrichment analysis of differentially abundant proteins associated with cellular components (F) and biological processes (G). Blue bars indicate proteins upregulated in poor-grade oocytes, whereas red bars indicate proteins downregulated in poor-grade oocytes. (H) Volcano plot showing differential protein abundance between excellent-grade and poor-grade oocytes, highlighting significantly altered proteins, including IRE1α. (I–K) RT-qPCR analysis of ER stress-associated transcripts in excellent-grade and poor-grade oocytes: (I) the ratio of spliced to unspliced XBP1 mRNA (XBP1s/XBP1u), (J) relative ATF6 mRNA expression, and (K) relative IRE1α (ERN1) mRNA expression. Each group comprised 250 oocytes. (L) Schematic of the experimental design used to assess meiotic maturation following treatment with tunicamycin ™ in excellent-grade oocytes, or tauroursodeoxycholic acid (TUDCA) and the IRE1α inhibitor STF-083010 (STF) in poor-grade oocytes, during in vitro maturation (IVM). (M–O) Quantification of the proportion of oocytes reaching metaphase II (MII) following pharmacological manipulation of ER stress signaling: (M) excellent-grade oocytes treated with or without TM; (N) poor-grade oocytes treated with or without STF; and (O) poor-grade oocytes treated with or without TUDCA. The numbers of oocytes analyzed are indicated above the bars. (P) Predicted secondary structure of QPRT mRNA showing a candidate stem– loop region containing a CUG motif. This computational prediction identifies a potential RNA structural feature for further investigation. (Q) Relative QPRT mRNA expression in excellent-grade oocytes and excellent-grade oocytes treated with TM, assessed by RT-qPCR. ® Relative QPRT mRNA expression in poor-grade oocytes following TUDCA treatment. (S) Relative IRE1α ( ERN1 ) mRNA expression in poor-grade oocytes following TUDCA treatment. (T) Schematic of the in vitro transcription and preparation of QPRT RNA substrates for the IRE1α-mediated RNA cleavage assay. (U) Representative RNA cleavage assay showing QPRT RNA incubated under the indicated conditions, including recombinant IRE1α. The accompanying table lists the sizes of the detected RNA products. (V) Schematic of the experimental workflow for assessing QPRT mRNA stability in excellent-grade and poor-grade oocytes following actinomycin D treatment to inhibit new transcription. (W) Relative QPRT mRNA abundance in excellent-grade and poor-grade oocytes at 0 and 3 h following actinomycin D treatment, assessed by RT-qPCR. Values are expressed relative to the corresponding 0-hr level. The number of oocytes analyzed is indicated above each graph. Data are presented as mean ± SEM. Statistical significance is indicated by asterisks (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Statistical significance was assessed using unpaired t-test and ordinary one-way ANOVA (N and O) and 2way ANOVA (W).

    Journal: bioRxiv

    Article Title: ER stress-associated IRE1α signalling links impaired QPRT-dependent NAD⁺ biosynthesis to reduced oocyte competence

    doi: 10.64898/2026.11.04.764453

    Figure Lengend Snippet: (A) Schematic of the workflow for comparative proteomic analysis of denuded excellent-grade and poor-grade goat oocytes, including protein extraction, LC–MS/MS analysis, and downstream protein profiling. (B) Venn diagram showing the overlap between proteins identified in excellent-grade and poor-grade oocytes. (C) Principal component analysis (PCA) showing separation of the proteomic profiles of excellent-grade and poor-grade oocytes. (D) Partial least squares discriminant analysis (PLS-DA) score plot illustrating differences in protein profiles between the two groups. (E) Heatmap showing the relative abundance of differentially abundant proteins in excellent-grade and poor-grade oocytes. (F,G) Gene Ontology (GO) enrichment analysis of differentially abundant proteins associated with cellular components (F) and biological processes (G). Blue bars indicate proteins upregulated in poor-grade oocytes, whereas red bars indicate proteins downregulated in poor-grade oocytes. (H) Volcano plot showing differential protein abundance between excellent-grade and poor-grade oocytes, highlighting significantly altered proteins, including IRE1α. (I–K) RT-qPCR analysis of ER stress-associated transcripts in excellent-grade and poor-grade oocytes: (I) the ratio of spliced to unspliced XBP1 mRNA (XBP1s/XBP1u), (J) relative ATF6 mRNA expression, and (K) relative IRE1α (ERN1) mRNA expression. Each group comprised 250 oocytes. (L) Schematic of the experimental design used to assess meiotic maturation following treatment with tunicamycin ™ in excellent-grade oocytes, or tauroursodeoxycholic acid (TUDCA) and the IRE1α inhibitor STF-083010 (STF) in poor-grade oocytes, during in vitro maturation (IVM). (M–O) Quantification of the proportion of oocytes reaching metaphase II (MII) following pharmacological manipulation of ER stress signaling: (M) excellent-grade oocytes treated with or without TM; (N) poor-grade oocytes treated with or without STF; and (O) poor-grade oocytes treated with or without TUDCA. The numbers of oocytes analyzed are indicated above the bars. (P) Predicted secondary structure of QPRT mRNA showing a candidate stem– loop region containing a CUG motif. This computational prediction identifies a potential RNA structural feature for further investigation. (Q) Relative QPRT mRNA expression in excellent-grade oocytes and excellent-grade oocytes treated with TM, assessed by RT-qPCR. ® Relative QPRT mRNA expression in poor-grade oocytes following TUDCA treatment. (S) Relative IRE1α ( ERN1 ) mRNA expression in poor-grade oocytes following TUDCA treatment. (T) Schematic of the in vitro transcription and preparation of QPRT RNA substrates for the IRE1α-mediated RNA cleavage assay. (U) Representative RNA cleavage assay showing QPRT RNA incubated under the indicated conditions, including recombinant IRE1α. The accompanying table lists the sizes of the detected RNA products. (V) Schematic of the experimental workflow for assessing QPRT mRNA stability in excellent-grade and poor-grade oocytes following actinomycin D treatment to inhibit new transcription. (W) Relative QPRT mRNA abundance in excellent-grade and poor-grade oocytes at 0 and 3 h following actinomycin D treatment, assessed by RT-qPCR. Values are expressed relative to the corresponding 0-hr level. The number of oocytes analyzed is indicated above each graph. Data are presented as mean ± SEM. Statistical significance is indicated by asterisks (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Statistical significance was assessed using unpaired t-test and ordinary one-way ANOVA (N and O) and 2way ANOVA (W).

    Article Snippet: STF-083010 ( MedChemExpress, HY-15845) was used to inhibit IRE1α activity.

    Techniques: Analysis, Protein Extraction, Liquid Chromatography with Mass Spectroscopy, Profiling, Quantitative Proteomics, Quantitative RT-PCR, Expressing, In Vitro, In Vitro Transcription, Cleavage Assay, Incubation, Recombinant, Stability, Significance Assay

    Characterization of DI/Ce6 and DI/Ce6@STF. (A, B) Representative electron microscopy images of DI/Ce6 and DI/Ce6@STF, respectively (scale bar: 100 nm); (C) Zeta potential of DI/Ce6 and DI/Ce6@STF; (D, E) Hydrodynamic particle size distributions of DI/Ce6 and DI/Ce6@STF measured by dynamic light scattering; (F) Particle size stability of DI/Ce6 and DI/Ce6@STF in PBS over 7 days; (G, H) Release Curves of DIABZI and STF-31 in DI/Ce6@STF; (I) Comparison of HPLC chromatograms for DI/Ce6@STF nanoparticles and free drug.

    Journal: Materials Today Bio

    Article Title: A photodynamically activated nanoplatform relieves glucose-driven immunosuppression to potentiate STING immunotherapy in triple-negative breast cancer

    doi: 10.1016/j.mtbio.2026.103071

    Figure Lengend Snippet: Characterization of DI/Ce6 and DI/Ce6@STF. (A, B) Representative electron microscopy images of DI/Ce6 and DI/Ce6@STF, respectively (scale bar: 100 nm); (C) Zeta potential of DI/Ce6 and DI/Ce6@STF; (D, E) Hydrodynamic particle size distributions of DI/Ce6 and DI/Ce6@STF measured by dynamic light scattering; (F) Particle size stability of DI/Ce6 and DI/Ce6@STF in PBS over 7 days; (G, H) Release Curves of DIABZI and STF-31 in DI/Ce6@STF; (I) Comparison of HPLC chromatograms for DI/Ce6@STF nanoparticles and free drug.

    Article Snippet: STF-31 (HY-18728), DIABZI (HY-112921A) and Ce6(HY-13594) were all purchased from MedChemExpress (Shanghai, China).

    Techniques: Electron Microscopy, Zeta Potential Analyzer, Comparison